Document:

Licensing and Distribution Agreement

 Exhibit 10.17 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Execution Copy 

LICENSING and DISTRIBUTION AGREEMENT 

by and between 

ZOGENIX, Inc. 

and 

DESITIN ARZNEIMITTEL GmbH 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 2

  

 TABLE OF CONTENTS 

 

					
	1.	  	DEFINITIONS	  	4
	2.	  	GRANT OF LICENSE	  	8
	3.	  	TRADEMARK	  	9
	4.	  	PRODUCT STEERING COMMITTEE (“SC”)	  	10
	5.	  	DEVELOPMENT AND COMMERCIALISATION OF THE PRODUCT	  	11
	6.	  	MANUFACTURE AND SUPPLY OF THE PRODUCT	  	12
	7.	  	MARKETING	  	14
	8.	  	PRICING	  	14
	9.	  	ROYALTIES	  	15
	10.	  	PAYMENT TERMS	  	16
	11.	  	RECORDS AND REPORTS	  	17
	12.	  	INFRINGEMENT OF RIGHTS BY THIRD PARTY	  	17
	13.	  	INFRINGEMENT OF THIRD PARTY RIGHTS	  	18
	14.	  	INDEMNIFICATION AND INSURANCE	  	19
	15.	  	IMPROVEMENTS AND PATENTS	  	21
	16.	  	RIGHT OF FIRST REFUSAL	  	22
	17.	  	REGULATORY	  	23
	18.	  	PHARMACOVIGILANCE	  	23
	19.	  	EXCHANGE OF INFORMATION	  	23
	21.	  	TERM AND TERMINATION	  	24
	22.	  	CONSEQUENCES OF TERMINATION	  	26
	23.	  	CONFIDENTIALITY	  	26
	24.	  	REPRESENTATIONS AND WARRANTIES	  	28
	25.	  	FORCE MAJEURE	  	29
	26.	  	NOTICES	  	29
	27.	  	ASSIGNMENT	  	30
	28.	  	GENERAL PROVISIONS	  	30

 LIST OF APPENDICES

  

			
	Appendix 1	  	Product Specification
	Appendix 2	  	Licensed Patents
	Appendix 3	  	Clinical Supply Terms

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 3

  

 LICENSING & DISTRIBUTION AGREEMENT 

THIS LICENSING & DISTRIBUTION AGREEMENT is entered into on this 14 day of March, 2008, by and between 

 

	 	1.	ZOGENIX, Inc. a company incorporated and existing under the laws of Delaware whose registered office is at 11682 El Camino Real, Suite 320, San Diego, CA 92130,
U.S.A. (“ZOGENIX”); 

 and 

 

	 	2.	DESITIN Arzneimittel GmbH, a company incorporated and existing under the laws of Germany whose registered office is at Weg beim Jaeger 214, 22335 Hamburg,
Germany (“DESITIN”); 

 Each also referred to as “Party” or together as
“Parties”. 
 RECITALS 
  

	 	A.	 ZOGENIX is, amongst others, active in the research and development of pharmaceuticals and medical devices and has developed Sumatriptan DosePro
TM for migraine patients for which ZOGENIX intends to
register the product in the U.S.A. 

  

	 	B.	DESITIN specialises in the manufacture, marketing and sale of branded pharmaceuticals, in particular CNS related products, in the Territory and desires to enter
into a contractual relationship with ZOGENIX to develop, obtain regulatory approval and commercialise the Product in the Territory. 

  

	 	C.	The Parties hereby enter into the Agreement on the terms and conditions as stipulated herein below. 

 NOW THEREFORE, the Parties hereby agree as follows: 

 

	1.	DEFINITIONS 

 As used in this Agreement,
unless expressly otherwise stated or evident in the context, the following terms shall have the meanings defined below. The singular (where appropriate) shall include the plural and vice versa and references to Appendices and Clauses shall mean
appendices and clauses of this Agreement. 
  

					
	1.1	  	Affiliate	  	shall mean any firm, person or company which controls, is controlled by or is under common control with a Party to this Agreement and, for the purpose of this definition, the term
“control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such firm, person or company, whether through the ownership of voting securities, by contract or
otherwise, or the ownership either directly or indirectly of 50% or more of the voting securities of such firm, person or company;
			
	1.2	  	Agreement	  	shall mean this licensing and distribution agreement and the appendices hereto;
			
	1.3	  	BfArM	  	shall mean Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices) in Germany, and any successor agency thereto;
			
	1.4	  	Business Day	  	shall mean any day other than Saturday or Sunday on which the banks in London are open for business;
			
	1.5	  	Clinical Trial Materials	  	shall mean the Product to be used by DESITIN in connection with the development and registration process in the Territory; for the avoidance of doubt Clinical Trial Materials shall
exclude all packaging and blinding thereof;
			
	1.6	  	Confidential Information	  	shall mean any scientific, technical, formulation, process, manufacturing, clinical, non-clinical, regulatory, marketing, financial or commercial information or data relating to the
business, projects or products of either Party and provided by one Party to the other by written, oral, electronic or other means in connection with this Agreement;
			
	1.7	  	cGMP	  	shall mean current good manufacturing practices as set out under the European Directive 2003/94/EC and promulgated by the International Conference on Harmonisation, as the same may
be modified or amended from time to time;
			
	1.8	  	“Cost of Goods Manufactured”	  	shall mean costs to produce Clinical Trial Materials and/or commercial supplies of Product to the extent that such costs would ordinarily be included as a Cost of Goods sold in
accordance with U.S. generally accepted accounting principles, including: [***];
			
	1.9	  	Change of Control	  	shall have the meaning as given to it in Clause 2.3;
			
	1.10	  	Committee Members	  	shall have the meaning as given to it in Clause 4.1;

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	Page 5

  

					
	1.11	  	Data	  	shall mean (a) written materials and information concerning the Product, including copies, or summaries, of materials prepared for submission to the Regulatory Authorities
concerning the Product or its labeling; (b) such clinical data and documentation in respect of the Product generated by research and trials funded by a Party or to which a Pary may have access with the right to disclose; and (c) safety information
in respect of the Product generated by a Party.
			
	1.12	  	DESITIN	  	shall have the meaning as given to it in Clause 2 of the recitals of this Agreement;
			
	1.13	  	DESITIN`s Net Sales	  	shall mean the gross price billed by DESITIN or its Affiliates to independent parties for sales of the Product less [***];
			
	1.14	  	DESITIN Parties	  	shall have the meaning as given to it in Clause 14.1;
			
	1.15	  	Dossier	  	shall mean the dossier of information and data filed, or to be filed with BfArM in relation with the application for Marketing Authorisation in Germany and other countries in the
European Union or with a comparable Regulatory Authority, including any amendments thereto;
			
	1.16	  	Effective Date	  	shall mean the date of this Agreement;
			
	1.17	  	Field	  	shall mean all therapeutic uses of the Product in humans;
			
	1.18	  	First Commercial Sale	  	shall mean the date of first invoice of Desitin for deliveries to wholesalers, hospital pharmacies, pharmacies or other independent parties;
			
	1.19	  	Force Majeure	  	shall mean in relation to either Party any circumstances beyond the reasonable control of that Party;
			
	1.20	  	Improvement	  	shall mean any discovery, development, invention, enhancement or modification, patentable or otherwise, relating to the Product in the Territory owned or controlled by ZOGENIX or
its Affiliates during the Term, including any modification or enhancement in the method of formulation, dosage strains, analytical methodology ingredients, preparation, presentation, means of delivery or administration, indication, use or packaging
of the Product. For the avoidance of doubt, “Improvement” shall not include Intellectual Property Rights which relate to line extensions of the Product or indications which are in addition to those for which ZOGENIX has requested Marketing
Authorisation in the United States on or before the Effective Date;
			
	1.21	  	Initial Term	  	shall have the meaning as given to it in Clause 21.1;
			
	1.22	  	Intellectual Property Rights	  	shall mean patents, trademarks, service marks, logos, trade names, rights and designs, copyright, utility models, rights and know how and other intellectual property rights, in each
case whether registered or unregistered and including applications for registration and all rights or forms of protection having equivalent or similar effect anywhere in the world;
			
	1.23	  	Key Facts	  	shall mean basic information used by DESITIN and its Affiliates in marketing or promoting the Product including but not limited to information on indications, dosage, side effects
and selling points used for the positioning within current and future market environment;
			
	1.24	  	Launch	  	means the commencement of commercial sale of the Product in the respective country of the Territory after receipt of Marketing Authorisation in that country of the
Territory;

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	Page 6

  

					
	1.25	  	Licensed Know-how	  	shall mean all information, procedures, instructions, techniques, data, technical information, knowledge and experience (including toxicological, pharmaceutical, clinical,
non-clinical and medical data, health registration data and marketing data), designs, sales and marketing materials and technology, including without limitation Data, owned or controlled by Zogenix during the Term and necessary to use, distribute,
sell, or offer for sale the Product in the Territory whether in written electronic or other form, including the Dossier. Notwithstanding the foregoing, Licensed Know-How shall exclude any and all Manufacturing Know-How;
			
	1.26	  	Licensed Patents	  	shall mean all Patent Rights owned or controlled by Zogenix during the Term and reasonably necessary to use, distribute, sell or offer for sale the Product in the Territory. As of
the Effective Date, the Licensed Patents consist of those Patents set forth on Appendix 2 to this Agreement;
			
	1.27	  	Licensed Technology	  	shall mean the Licensed Know How and the Licensed Patents and any Improvements thereto;
			
	1.28	  	Manufacturing Agreement	  	Shall mean the agreement to be entered into by the Parties as set out in Clause 6.2 and pursuant to which ZOGENIX shall be the exclusive supplier of all of DESITIN’s, its
Affiliates’ and its permitted sub-licensees’ requirements of Product for commercial use and/or sale in the Territory;
			
	1.29	  	Manufacturing Know-How	  	shall mean any and all of the following, to the extent both (a) owned or controlled by Zogenix or any respective Affiliate of Zogenix (other than an Acquiror of Zogenix), as the
case may be, and (b) related to Products: methods of manufacturing, production and test methods, procedures and batch records, manufacturing and testing summary data, process and assay validation information, and any other information, procedures,
instructions, techniques, data, technical information, knowledge and experience (including regulatory) related to manufacturing, manufacturing process development and scale-up, manufacturing capacity, manufacturing facilities, product testing,
product release, quality assurance activities, or stability tests;
			
	1.30	  	Marketing Authorisation	  	shall mean the grant of all necessary permits, authorisations, licences and approvals (or waivers) from any Regulatory Authority required for the research, development, manufacture,
promotion, storage, import, export, transport or use of the Product in the Territory;
			
	1.31	  	MOH	  	shall mean the Ministry of Health or equivalent governmental body responsible for granting Marketing Authorisation in each respective country within the Territory;
			
	1.32	  	Other Territories	  	shall mean the world except for the Territory;
			
	1.33	  	Party	  	shall have the meaning as given to it in the Preamble;
			
	1.34	  	Patent Rights	  	shall mean patents or patent applications; and any divisionals, continuations, substitutions, continuations-in-part, extensions, renewals, re-examinations or reissues of such
patents or applications, as applicable, in each case in the Territory;
			
	1.35	  	Pharmaco-vigilance Agreement	  	shall mean the agreement to be entered into by the Parties as set out in Clause 18.1 and pursuant to which the Parties shall fulfil the applicable pharmaceutical rules and
regulations in the Territory and the Other Territories;

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	Page 7

  

					
	1.36	  	Product	  	shall mean the medical device DosePro with Sumatriptan as the sole active ingredient as specified in the Product Specification;
			
	1.37	  	Product Specification	  	shall mean the specifications as defined for the Product in Appendix 1 to this Agreement;
			
	1.38	  	Reasonable Commercial Efforts	  	shall mean commercial efforts consistent with normal business practices and effort used by a Party in connection with other products of similar market size or importance which such
Party intends to launch or has launched and sold in the relevant Territory, or in the absence of any such similar products then such efforts shall be assessed by reference to good business practice in the light of all the
circumstances;
			
	1.39	  	Regulatory Authority	  	shall mean any and all governmental and regulatory bodies, agencies, departments or entities, whether or not located in the Territory, which regulate, direct or control commerce in
or with the Territory, including any competent agency, body or entity from time to time responsible for granting Marketing Authorisations;
			
	1.40	  	Remedies	  	shall have the meaning as given to it in Clause 12.1;
			
	1.41	  	ROFR	  	shall have the meaning given to it in Clause 16;
			
	1.42	  	Royalty	  	shall have the meaning as given to it in Clause 9.1;
			
	1.43	  	Samples	  	shall mean certain quantities of the Product to be used in the Territory for advertising and marketing purposes only, any sale being strictly prohibited;
			
	1.44	  	Term	  	shall mean the Initial Term as the same may be extended pursuant to Clause 21.2.
			
	1.45	  	Territory	  	 shall mean the countries of the European Union (defined below and thereafter as constituted from time to time) plus Norway, Switzerland
and Turkey, to the extent not otherwise included in the European Union:
  

The countries of the European Union as of the Effective Date are as follows:

Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom;

			
	1.46	  	Third Party	  	shall mean any person or entity who or which are neither a Party nor an Affiliate of a Party;
			
	1.47	  	Trademark	  	shall mean the trademark “DosePro” or any trademark containing “DosePro” or such other substitute trademark as Zogenix following consultation with DESITIN
determines to use instead of “DosePro”. For the avoidance of doubt, “Trademark” does not include the trademark ZogenixTM and any other related trademark or service mark (whether registered or unregistered) containing the word
“Zogenix”;
			
	1.48	  	Transfer Price	  	shall have the meaning as given to it in Clause 8.3;
			
	1.49	  	ZOGENIX	  	shall have the meaning as given to it in Clause 1 of the recitals to this Agreement;
			
	1.50	  	ZOGENIX Parties	  	shall have the meaning as given to it in Clause 14.2.

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 8

  

	2.	GRANT OF LICENSE 

  

	2.1	Subject to the terms of this Agreement, ZOGENIX hereby grants to DESITIN an exclusive license under the Licensed Technology to develop, use, distribute, sell,
offer for sale, and import the Product in the Field and in the Territory. 

  

	2.2	The term “exclusive” for the purposes of clause 2.1 means to the exclusion of all others, including ZOGENIX and its Affiliates, except to the extent
necessary to enable ZOGENIX to perform its obligations under this Agreement. 

  

	2.3	DESITIN shall have the right to sub-license all or any of the rights licensed under this Agreement to its Affiliates and any Third Party, provided that DESITIN
shall: 

  

	 	(a)	provide ZOGENIX with a copy of such sub-license agreement promptly after the execution of any sub-license covering the Territory, which sub-license agreement is
consistent with the terms of this Agreement insofar as they are applicable, but excluding the right to grant a sublicense, and contains terms that are no less restrictive than those contained in this Agreement on audit, inspection, and
confidentiality; 

  

	 	(b)	if the sub-licensee is not an Affiliate of DESITIN seek ZOGENIX’s prior written consent, which consent shall not be unreasonably withheld; provided that ZOGENIX
may request adequate background and other information on the proposed sub-licensee and if DESITIN is unable to reasonably satisfy ZOGENIX as to such background and other information or that ZOGENIX will continue to receive the economic benefit of
its bargain as if DESITIN were continuing to market and promote the Product under this Agreement, ZOGENIX may withhold its consent; 

  

	 	(c)	if the sub-licensee is an Affiliate of DESITIN at the time of the sub-license hereunder and thereafter the sub-licensee ceases to be an Affiliate of DESITIN (a
“Change of Control”), unless ZOGENIX grants its prior written consent (pursuant to the procedure set forth in Clause 2.3(b)) it is agreed that the sub-license granted to former Affiliates of DESITIN shall automatically
terminate when the Change of Control becomes effective; and 

  

	 	(d)	DESITIN shall be liable to ZOGENIX for acts or omissions of any Affiliate or permitted sub-licensee and shall solely be responsible for any claim made by any Affiliate
or permitted sub-licensee against ZOGENIX; provided that in each case, such claims do not arise from any act or omission of the ZOGENIX Parties. 

  

	2.4	The license granted under Clause 2.1 includes sub-licenses under any Intellectual Property Rights included within the Licensed Technology which have, prior to
the Effective Date, been licensed by ZOGENIX from any Third Party. Any royalties or other payments due to any Third Party pursuant to such a Third Party license shall be paid by ZOGENIX. 

 

	2.5	Each Party shall have access to the other Party’s Data and shall have a right to use such Data in their respective territories. For the avoidance of doubt,
DESITIN’s right to use the Data shall be limited to its use in satisfying its obligations or pursuing its rights under this Agreement during the Term and ZOGENIX shall have a perpetual right to use the Data of DESITIN during the Term and
following any expiration or termination of this Agreement. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 9

  

	2.6	Notwithstanding anything in this Agreement to the contrary, ZOGENIX shall, as between the Parties, retain: (a) the exclusive right to manufacture and supply
Product for all fields of use; and (b) develop, register, import, export, use, and sell the Product outside the Territory. 

  

	2.7	ZOGENIX reserves the right to modify and/or to discontinue developing or producing the Product at its discretion at any time either (1) due to legal or
regulatory requirements, administrative or court orders, or safety risks, or (2) so long as the Product in question is withdrawn from the market throughout the European Union for a justified and reasonable motive; provided, however, that
ZOGENIX shall notify DESITIN as soon as practicable after any such modification or discontinuance and DESITIN shall be entitled to market any modified versions of Product pursuant to the terms of this Agreement. Nothing in this Agreement shall be
deemed to restrict ZOGENIX from selling the Product or other products to Persons outside the Territory. ZOGENIX shall not authorize purchasers or distributors in Other Territories to sell the Product in the Territory. However, if by operation of
law, the purchasers or distributors in Other Territories are permitted to sell the Product in the Territory, DESITIN shall receive no compensation. 

  

	3.	TRADEMARK 

  

	3.1	Subject to the terms of this Agreement, ZOGENIX hereby grants to DESITIN, its Affiliates and permitted sub-licensees a license to the Trademark for no additional
consideration. 

  

	3.2	DESITIN will use the Trademark to identify the Product and in its development and commercialisation of the Product in the Territory. Therefore, DESITIN shall use
the Trademark as part of the Product name along with such other words as ZOGENIX and DESITIN shall mutually agree are appropriate for the commercialisation of the Product in the Territory. The Trademark shall be owned and registered by ZOGENIX or
its nominee and ZOGENIX or its nominee shall ensure that the registration of such Trademark is kept valid within the Territory, unless otherwise agreed upon between the Parties in writing. 

 

	3.3	The Trademark shall only be used in connection with sale and marketing of the Product within the Field and other activities pursuant to this Agreement in the
Territory. 

  

	3.4	DESITIN shall ensure that each use by it, its Affiliates and permitted sub-licensees of the Trademark is accompanied by an acknowledgement that the Trademark is
owned by ZOGENIX. DESITIN, its Affiliates and permitted sub-licensees shall not (A) use the Trademark in a way that might materially prejudice its distinctiveness or validity or the goodwill of ZOGENIX therein, or (B) use any trademarks or
trade names so resembling the Trademark as to be likely to cause confusion or deception. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 10

  

	3.5	DESITIN shall not have, assert or acquire any right, title or interest in or to the Trademark or the goodwill pertaining thereto, except as explicitly provided
in Clause 3.1 of this Agreement. 

  

	3.6	DESITIN shall give ZOGENIX prompt notice of any infringement or threatened infringement of the Trademark. ZOGENIX shall determine in its sole discretion what
action, if any, to take in response to the infringement or threatened infringement of the Trademark. 

  

	4.	PRODUCT STEERING COMMITTEE (“SC”) 

  

	4.1	The Parties shall establish a SC consisting of four (4) individuals (“Committee Members”); two of whom shall be
nominated by ZOGENIX; and two of whom shall be nominated by DESITIN. The Committee Members may be replaced by written notice to the other Party and shall be appropriately qualified and experienced in order to make a meaningful contribution to SC
meetings. 

  

	4.2	The purpose of the SC is to provide a forum for the Parties to share information on the ongoing research, development and commercialisation of the Product
including monitoring progress of clinical studies, reviewing clinical trial programmes, considering proposed marketing and promotional plans, reviewing competitor activity and discussing any regulatory, technical, quality assurance or safety issues
in relation to the Product. 

  

	4.3	The SC shall ensure the mutual exchange of Data, whether derived by Zogenix or DESITIN or their respective Affiliates or permitted sub-licensees. Each Party
shall provide to the other Party such assistance as is reasonably necessary in respect of Regulatory Approvals in their respective territories, and in particular shall provide access to such Party’s Data, to the extent the Party providing such
access is is legally and contractually permitted to do so, and, with respect to ZOGENIX providing DESITIN access, limited to DESITIN’s use in obtaining Regulatory Approvals in respect of the Product. 

 

	4.4	The SC shall meet as often as the Committee Members may determine, but in any event not less than twice per calendar year until approval of the first Marketing
Authorisation and at least annually in the subsequent commercialisation period. Either Party may request additional SC meetings insofar it deems necessary for the development or commercialisation of the Product in the Territory. The Committee
Members may invite individuals with special skills to attend meetings where it is considered to be relevant and appropriate. The quorum for SC meetings shall be two Committee Members, comprising one Committee Member from each Party. Each SC meeting
shall be chaired by ZOGENIX. The Parties shall act in good faith and cooperate with one another in the development, marketing and commercialisation of the Product in the Territory. 

 

	4.5	The SC shall take its decisions unanimously. In the event the SC is unable to take a decision unanimously, ZOGENIX shall have the final say on development and
manufacturing matters related to the Product in the Territory and DESITIN shall have final say on commercialisation matters related to the Product in the Territory (provided that DESITIN shall consult with ZOGENIX and consider any input received
from ZOGENIX with respect to any pricing discussions with Regulatory Authorities related to the Product in the Territory). 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 11

  

	5.	DEVELOPMENT AND COMMERCIALISATION OF THE PRODUCT 

  

	5.1	ZOGENIX shall, within [***] days from the Effective Date, deliver to DESITIN (to the extent available) the Licensed Know-How as of the Effective Date, to the
extent that ZOGENIX is legally and contractually permitted to do so, and as required for the development, regulatory approval, commercialisation or use of the Product in the Territory. 

 

	5.2	DESITIN shall, at its sole cost, use Reasonable Commercial and scientific Efforts (without being required to use all available resources) to develop, obtain
Marketing Authorisation(s) and commercialise the Product in the Territory, including obtaining all required approvals to market the Product in the Territory. DESTIN shall conduct its activities hereunder in a lawful manner and in accordance with the
well-established pharmaceutical product development and commercialisation practices and the competition law applicable in each respective country in the Territory, and shall cause its employees, Affiliates and permitted sub-licensees to do the same.
In particular DESITIN shall take all necessary steps to obtain Marketing Authorisation and prepare the Launch of the Product in Germany. In exploring in which other countries of the Territory the obtaining of Marketing Authorisation and the
subsequent marketing of the Product, whether by DESITIN or DESITIN’s Affiliates or by local distribution partners, is likely to be profitable and commercially feasible, DESITIN will focus on France, Italy, Spain, the United Kingdom, Denmark,
Sweden and Finland. Launch of the Product in the remaining countries of the Territory will be considered at a later stage and shall be mutually agreed. 

  

	5.3	DESITIN shall not be required to conduct any clinical or non-clinical trials, except only for one (1) study regarding bioequivalence of the Product provided
that such study is required by a competent Regulatory Authority. 

  

	5.4	The Parties shall consult on an ongoing basis as to the preparation, filing, pursuit and maintenance of regulatory submissions under this Clause 5 and no such
submission shall be made by DESITIN without ZOGENIX’s prior written approval, not to be unreasonably withheld. DESITIN shall keep ZOGENIX informed, in writing, of the status of its applications for Marketing Authorisations on a regular basis,
and in any event no less frequently than once every three months, and shall immediately notify ZOGENIX in writing of any substantial change in the status of any Marketing Authorisation or any substantive questions received from any Regulatory
Authority in respect of such Marketing Authorisations. DESITIN shall provide copies of all Marketing Authorisations to ZOGENIX at its request. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 12

  

	5.5	Once Marketing Authorisation is granted in Germany without any qualifications, DESITIN hereby undertakes to ZOGENIX that it will Launch the Product in Germany no
later than [***] ([***]) months after the date of the relevant Marketing Authorisation; provided that such time period shall be extended by the time period during which ZOGENIX fails to timely supply DESITIN with Product which has been
properly ordered pursuant to the terms of the applicable supply agreement. Should DESITIN fail to Launch the Product in accordance with this Clause 5.5, DESITIN further undertakes to ZOGENIX that it will promptly notify ZOGENIX of such failure
which shall be deemed a material breach of this Agreement 

  

	5.6	Once Marketing Authorisation is granted in any country of the Territory other than Germany without any qualifications, DESITIN shall (i) verify the
profitability of a possible Launch of the Product in the respective country and (ii) subject to the verification of the profitability for such country in the Territory, Launch the Product as soon as reasonably practicable and commercially
viable. 

  

	5.7	ZOGENIX shall use Reasonable Commercial Efforts to assist DESITIN to solve material issues which may arise after discussions with Regulatory Authorities on the
Product. 

  

	5.8	ZOGENIX, to the extent it is legally and contractually permitted to so do, shall take all steps which may be required by law and shall sign all necessary
documents and perform all commercially reasonable obligations which may be required in order to assure that DESITIN may market, sell and distribute the Product in the Territory under its own company name and in the manner it regards as appropriate
subject to the terms of this Agreement and any possible restrictions caused by Marketing Authorisations. 

  

	5.9	The licences granted under Clauses 2.1 and 3.1 of this Agreement will become non-exclusive in the event that DESITIN (i) will not start the study regarding
bioequivalence of the Product as referred to in Clause 5.3 within [***] ([***]) months following the receipt of the Licensed Know-How as of the Effective Date according to Clause 5.1 or (ii) has not filed a Marketing Authorisation for the
Product in Germany within [***] ([***]) months after the completion of such bioequivalence study or (iii) otherwise adhere to a mutually agreed timeline for the execution of clinical trials and submissions of Marketing Authorisations throughout
the Territory. 

  

	5.10	To the extent permissible by law, DESITIN is prohibited from advertising, circulating price lists or otherwise soliciting orders for the Product, and from
establishing or maintaining branches, sales offices or distribution depots, outside the Territory for the distribution of the Product. 

  

	6.	MANUFACTURE AND SUPPLY OF THE PRODUCT 

  

	6.1	Clinical Supply. ZOGENIX shall be the exclusive supplier of all of DESITIN’s requirements for Clinical Trial Materials in the Territory at ZOGENIX’s
Cost of Goods Manufactured. DESITIN shall purchase all of its requirements of Clinical Trial Materials in the Territory from ZOGENIX. Additional terms under which ZOGENIX shall supply Clinical Trial Materials in the Territory are set forth on
Appendix 3. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 13

  

	6.2	Commercial Supply. The Parties shall use Reasonable Commercial Efforts to sign the Manufacturing Agreement no later than [***] ([***]) months prior to the
anticipated first Launch of the Product in the Territory. The Manufacturing Agreement shall contain the terms set forth in this Clause 6.2 through Clause 6.6 and such other commercially reasonable and customary terms and conditions to be mutually
agreed by the Parties (including the right of DESITIN to audit ZOGENIX’s (or its Third Party contract manufacturer’s) manufacturing facilities and a forecasting mechanism which will permit ZOGENIX to properly manage its supply chain for
the Product on a worldwide basis) and such other terms as are reasonable and customary in the commercial supply of pharmaceutical compounds; provided that the Manufacturing Agreement shall be subject to the terms of any manufacturing agreement which
ZOGENIX puts into place with respect to the commercial supply of Product in the Other Territories 

  

	6.3	DESITIN acknowledges and agrees that ZOGENIX will manufacture the Product or will enter into a contractual relationship with one or several manufacturers of the
Product. Such Third Party manufacturers shall be listed in the registration documentation and manufacture the Product on ZOGENIX’s behalf in accordance with applicable law in the Territory. 

 

	6.4	Any Products supplied by ZOGENIX hereunder shall be manufactured: 

  

	 	(a)	in accordance with cGMP; 

  

	 	(b)	in compliance with the Product Specification; and 

  

	 	(c)	in compliance with all applicable and relevant national and local laws, rules and regulations, including those promulgated by any relevant Regulatory Authority.

  

	6.5	The Product shall be supplied by ZOGENIX to DESITIN as finished products ready for final packing and labelling as required in each country of the Territory
(DESITIN will be responsible for such items as set forth in Clause 7.3 as well as quality control, in each case at its own expense). Each shipment of the Product shall be accompanied by the corresponding analytical certificate attesting to the
Product’s compliance with the specification approved by the Regulatory Authority in the Territory. The Product shall be placed at DESITIN’s disposal EXW (Incoterms 2000) ZOGENIX’s manufacturing facility at such address as is notified
to DESITIN from time to time in writing. 

  

	6.6	ZOGENIX shall deliver commercial supply of the Product to DESITIN in complete batch quantities whereby each batch shall have a minimum remaining shelf life of
[***] percent ([***]%) of the shelf life approved by the United States Food and Drug Administration in the Marketing Authorisation submitted by ZOGENIX on its own behalf. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 14

  

	7.	MARKETING 

  

	7.1	DESITIN shall inform ZOGENIX [***] ([***]) months before the anticipated date of the first Launch of the Product in the Territory of the Key Facts of its
proposed promotion strategy regarding the Product. DESITIN shall provide ZOGENIX with copies of all promotional materials to be used in connection with the marketing and/or promotion of the Product in the Territory prior to their use. The materials
shall be submitted in the language(s) of the country or countries where they are to be used. ZOGENIX shall use Reasonable Commercial Efforts to provide a written response, either approving or suggesting reasonable changes, within [***] ([***]) weeks
of receipt of such Key Facts or promotional materials. If DESITIN does not receive a written response from ZOGENIX within this [***]-week period ZOGENIX shall be deemed to have given its approval. In case ZOGENIX does not agree with the provided Key
Facts or other statements contained in any promotional materials, ZOGENIX and DESITIN agree to discuss the Key Facts or such other statements, as applicable, in good faith. After written approval by ZOGENIX which shall not be unduly withheld or
delayed, DESITIN shall carry out marketing and promotional activities in relation to the Product in the Territory in compliance with the approved Key Facts, promotional materials and all applicable laws, rules and regulations.

  

	7.2	During the Term, DESITIN shall not, and shall ensure that its Affiliates and permitted sub-licensees shall not, market, sell, promote or distribute the Product
in the Other Territories. 

  

	7.3	DESITIN shall be responsible, at its cost, for final packaging and labelling of Product in accordance with the requirements for each country of the Territory.

  

	7.4	DESITIN shall be free to set any price for the Product in the Territory subject to discussion by the SC as provided in Clause 4.4 and applicable pharmaceutical
regulations. 

  

	7.5	Except to the extent permitted by law and as may be agreed in writing between the Parties, DESITIN shall not market, sell, promote or distribute the Product in
the respective country in the Territory unless and until DESITIN obtains the appropriate Marketing Authorisations in respect of such Product in the respective country in the Territory. 

 

	8.	PRICING 

  

	8.1	DESITIN shall purchase the Product for commercial sale from ZOGENIX at the greater of (a) the agreed Transfer Price as defined in Clause 8.3 or
(b) Cost of Goods Manufactured (collectively, the “Purchase Price”). In the event that Purchase Price is greater than the higher of [***]€ or US$[***], DESITIN shall have the right to terminate this Agreement as set forth in
Section 21.7. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 15

  

	8.2	Transfer Price shall be subject to adjustment on an annual basis beginning in 2009 based on data for the prior year (e.g., increases for information reported for
2008 shall apply to 2009 Transfer Prices) as of May 31 beginning with May 31, 2009, in accordance with the annual percentage change in the European pricing index of industrial products (“Erzeugerpreise industrieller Produkte auf dem
Inlandsmarkt—Gesamte Industrie ohne Baugewerbe—Eurozone”; Source: EUROSTAT), except as otherwise mutually agreed by the Parties. 

  

	8.3	The Transfer Price (EXW (Incoterms 2000)) shall be calculated according to the following table and subject to adjustment as set forth in Clause 8.2:

  

				
	 Annual Units
	  	 Transfer Price (EUR)
	 
	[***]	  	[	***] 
	[***]	  	[	***] 
	[***]	  	[	***] 

 By way of
example, if DESITIN or its Affiliates were to purchase an aggregate of [***] units in a calendar year 2008, the total Transfer Price for such calendar year would be calculated as follows: ([***] x [***]€) + ([***] x [***]€) + ([***] x
[***]€) = [***]€. 
  

	9.	ROYALTIES 

  

	9.1	DESITIN shall pay ZOGENIX a royalty equal to [***]% of the DESITIN’s Net Sales (“Royalty”). 

 

	9.2	Royalties will not be payable on sales realised by regional distributors or Third Parties so long as such sales have been included in DESITIN’s Net Sales
upon first sale or distribution to such regional distributors or Third Parties or are otherwise invoiced directly by DESITIN and as a result included in DESITIN’s Net Sales. 

 

	9.3	No Royalties shall accrue on the disposition of the Product as Samples (promotional or otherwise), donations or for clinical trials, provided that such level of
sampling or donations are generally consistent with industry standards and in any event after expiry of [***] ([***]) months upon Launch does not exceed [***]% of the gross revenues of the Product in the Territory. 

 

	9.4	The obligation to pay a Royalty under Clause 9.1 for a Product shall continue throughout the Term. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 16

  

	10.	PAYMENT TERMS 

  

	10.1	DESITIN shall make any other payments than Royalties due under this Agreement in United States Dollars within [***] ([***]) days of receipt of the invoice for
Product (which date shall be no earlier than the date of delivery of the Product). Invoices shall be sent via fax and by internationally recognized overnight courier to DESITIN’s address for notices hereunder. 

 

	10.2	All right, title and risk in the Product passes to DESITIN upon delivery of Product to DESITIN in accordance with this Agreement. 

 

	10.3	DESITIN agrees to make payments and written reports to ZOGENIX within [***] ([***]) days after the end of each calendar quarter covering all sales of the Product
in the Field in the Territory by DESITIN, its Affiliates or permitted sub-licensees for which invoices were sent during such calendar quarter, each such written report stating for the period in question: (i) for Product disposed of in the
Territory by sale, the quantity and description of Product, (ii) for Product disposed of in the Territory other than by sale, the quantity, description, and nature of the disposition, (iii) the calculation of DESITIN’s Net Sales for
such quarter and year-to-date DESITIN’s Net Sales; and (iv) the calculation of the amount due to ZOGENIX for such quarter pursuant to Clause 9 on account of such DESITIN’s Net Sales. The information contained in each report under this
Clause 10.3 shall be considered Confidential Information of DESITIN. Concurrent with the delivery of each quarterly report, DESITIN shall make the payment due ZOGENIX hereunder in United States Dollars for the calendar quarter covered by such
report. 

  

	10.4	All amounts not paid to the other Party when due shall accrue interest daily at the lesser of an annual rate of (a) [***] or (b) [***].

  

	10.5	All sums payable hereunder are expressed to be exclusive of VAT or other similar tax. Notwithstanding the foregoing, any income or other taxes on any monies
payable to ZOGENIX which DESITIN is required by law to pay or withhold on behalf of ZOGENIX, shall be deducted by ZOGENIX from such monies due. DESITIN shall furnish ZOGENIX with proof of such payments. Any such tax required to be paid or withheld
shall be an expense borne solely by DESITIN, and ZOGENIX may request reimbursement from DESITIN for any such amounts. DESITIN shall promptly provide ZOGENIX with a certificate or other documentary evidence to enable ZOGENIX to support a claim for a
refund or a foreign tax credit with respect to any such tax so withheld or deducted by DESITIN. At ZOGENIX’s request, DESITIN shall reasonably cooperate to support any claim by ZOGENIX for such a refund or credit. The Parties will reasonably
cooperate in completing and filing documents under the provisions of any applicable tax treaty or under any other applicable law, in order to enable DESITIN to make such payments to ZOGENIX without any deduction for withholding.

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 17

  

	11.	RECORDS AND REPORTS 

  

	11.1	During the Term, DESITIN shall, and shall procure that its Affiliates shall, keep at its normal place of business full, complete, accurate and up to date records
and books of account recording DESITIN’s Net Sales sufficient to ascertain the Royalties payable under this Agreement. 

  

	11.2	Upon no less than [***] ([***]) Business Days notice from ZOGENIX, DESITIN shall make such records and books of account available for audit during business hours
to ZOGENIX or its nominee (but not more than [***] in any calendar year). 

  

	11.3	ZOGENIX shall be solely responsible for its costs and expenses in making any such audit and inspection unless ZOGENIX properly identifies a discrepancy in the
Royalties paid in any calendar year from those properly payable under this Agreement for that calendar year of greater than [***]%, in which event DESITIN shall pay ZOGENIX’s reasonable cost incurred in connection with the audit and inspection,
and promptly make good the deficit in the Royalty payments. Upon the expiration of [***] months from the end of any calendar year the calculation of Royalties payable with respect to such year shall be binding and conclusive, and DESITIN shall be
released from any liability or accountability with respect to Royalties for such year. 

  

	11.4	All information disclosed by DESITIN, its Affiliates or its permitted sub-licensees pursuant to Clauses 11.1 through 11.3 shall be deemed Confidential
Information of DESITIN, its Affiliates or its permitted sub-licenses, as the case may be. 

  

	11.5	DESITIN shall advise ZOGENIX of any legislation, rule, regulation or other law (including but not limited to any customs, tax, foreign exchange or foreign trade,
antimonopoly, pharmaceutical products or intellectual property law) which is in effect or which may come into effect in the Territory after the date of this Agreement and which may affect the importation of the Products into the Territory or the use
of the Products or the protection of the Licensed Technology as soon as DESITIN received notice thereof or would otherwise reasonably be expected to have notice thereof. 

 

	12.	INFRINGEMENT OF RIGHTS BY THIRD PARTY 

  

	12.1	ZOGENIX shall have the first right, but not the obligation, to take action in respect of any infringement of the Licensed Technology in the Territory, including
but not limited to, commencing any claim or proceedings for injunctive, compensatory or other remedies or relief (collectively “Remedies”) as may be necessary or desirable to prevent such infringement and preserve the Licensed
Technology. DESITIN shall permit any such Remedies to be brought in its name if permitted or required by law. ZOGENIX may compromise or settle any of the Remedies in its sole discretion, provided that, ZOGENIX shall not make any settlement or
compromise that adversely affects the interests of DESITIN in respect of the Product in the Territory without the prior consent of DESITIN, such consent not to be unreasonably withheld or delayed. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 18

  

	12.2	In the event that ZOGENIX elects not to pursue any Remedies with respect to the Licensed Technology in the Territory within [***] ([***]) days after notice in
writing from DESITIN requesting ZOGENIX to do so, DESITIN shall have the right, but not the obligation, to pursue Remedies against such Third Party infringer, provided that: 

 

	 	(a)	DESITIN does not make any settlement or compromise that affects the interests of ZOGENIX in the Product without the prior written consent of ZOGENIX, such consent not
to be unreasonably withheld or delayed; and 

  

	 	(b)	if ZOGENIX has commenced negotiations with such Third Party for discontinuance of the infringement within such [***] ([***]) day period, ZOGENIX shall have an
additional [***] ([***]) day period to conclude its negotiations before DESITIN may pursue any Remedies under this Clause 12.2. 

  

	12.3	In the event that either Party pursues the Remedies under clauses 12.1 or 12.2: 

 

	 	(a)	the other Party shall use all reasonable efforts to assist and cooperate with the Party pursuing such Remedies, including providing access to relevant materials,
personnel, documents and other evidence; and 

  

	 	(b)	each Party shall bear its own costs and expenses relating to its pursuit of Remedies or in providing assistance and cooperation; and 

 

	 	(c)	any damages or other amounts awarded to either Party shall be distributed as follows: 

 

	 	(i)	to the Party that pursued the Remedies, to cover its legal costs and expenses incurred; and then 

 

	 	(ii)	to the other Party, to cover its legal costs and expenses, if any, relating to the pursuit of such Remedies; and then 

 

	 	(iii)	any remaining amount, after the deductions set out above shall be retained by DESITIN, except that ZOGENIX shall receive a portion equivalent to the Royalties it would
have received under this Agreement if such remaining amount were deemed DESITIN’s Net Sales. 

  

	13.	INFRINGEMENT OF THIRD PARTY RIGHTS 

  

	13.1	In the event that a Third Party institutes or threatens to institute a patent, trade secret or other infringement proceeding against either Party or its
Affiliates during the Term, alleging that its or their manufacture, use or sale of the Product in the Territory infringes the Third Party’s Intellectual Property Rights (a “Third Party Action”), each Party shall promptly notify the
other of the Third Party Action with such details as it has in its possession and the Parties shall promptly convene a meeting of the SC to discuss the best way to respond. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 19

  

	13.2	Upon receipt of any such notice the SC shall discuss the potential infringement and to the extent necessary attempt to agree on a course of action. Such course
of action may include: 

  

	 	(a)	obtaining an appropriate license from the Third Party; 

  

	 	(b)	contesting any claim or proceedings brought by the Third Party; or 

  

	 	(c)	bringing a declaratory judgment action against such Third Party. 

  

	13.3	ZOGENIX shall have the first right but not the obligation, to take any action agreed upon by the Parties in respect of the Third Party Action. If within [***]
days the Parties fail to agree upon an appropriate course of action through discussions of the SC, ZOGENIX may decide upon the course of action with respect to any Third Party Action and may commence such action or negotiate a license with such
infringed Third Party. 

  

	13.4	Neither Party shall settle any Third Party Action relating to the Product if such settlement admits the invalidity or unenforceability of any of the Licensed
Technology, except as agreed in writing between the Parties. 

  

	13.5	In the event that the SC determines that DESITIN is best positioned to commence any action in relation to or defence of the Third Party Action, DESITIN shall be
entitled to credit up to [***]% of its reasonable costs and expenses (including legal and expert fees) or any Third Party royalties incurred against any royalty payment otherwise payable to ZOGENIX under this Agreement. In the event that no such
royalty payments are payable by DESITIN under this Agreement at the time of the Third Party Action, up to [***]% of any reasonable costs and expenses or Third Party royalties incurred by DESITIN in connection with the Third Party Action shall be
reimbursed by ZOGENIX on a Quarterly basis. In addition, in any such action which DESITIN commences as permitted by this Clause 13, DESITIN shall seek ZOGENIX’s consent prior to concluding any settlement agreement, which consent can be withheld
in its sole discretion. 

  

	13.6	In any such Third Party Action, the Parties shall cooperate with each other in connection with any such claim, suit or proceeding and shall keep each other reasonably
informed of any material developments in connection with any such claim, suit or proceeding, including providing access to relevant documents, material, personnel or other evidence. 

 

	14.	INDEMNIFICATION AND INSURANCE 

  

	14.1	ZOGENIX shall defend, indemnify and hold harmless DESITIN, its Affiliates and its and their officers, directors, employees, agents and contractors
(“DESITIN Parties”) from and against any and all claims, actions, demands, losses, damages, costs and reasonable expenses (including reasonable legal and expert fees) made or brought by Third Parties (“Claims”)
arising from or in connection with: 

  

	 	(a)	the personal injury or death caused by the defective design and/or manufacture of the Product when supplied to DESITIN by ZOGENIX or its designee; or

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 20

  

	 	(b)	the breach of the warranties given by ZOGENIX under this Agreement, or 

  

	 	(c)	the negligence of ZOGENIX Parties (as defined below) in the research, development, marketing, distribution, sale or use of the Product before the Effective Date both in
or outside the Territory, or 

  

	 	(d)	the negligence of ZOGENIX Parties in the research, development, marketing, distribution, sale or use of the Product following the Effective Date outside the Territory,

  

	 	provided	that, in each case, such Claims do not arise from the negligence or wilful default of the DESITIN Parties. 

 

	14.2	DESITIN shall defend, indemnify and hold harmless ZOGENIX, its Affiliates and its and their officers, directors, employees, agents and contractors (the
“ZOGENIX Parties”) from and against any and all Claims arising from or in connection with: 

  

	 	(a)	the development, marketing, distribution, sale or use of the Product in the Territory after the Effective Date; 

 

	 	(b)	the negligence by DESITIN Parties in relation to the development, marketing, distribution, sale or use of the Product in the Territory after the Effective Date; or

  

	 	(c)	the breach of the warranties given by DESITIN under this Agreement, 

provided that, in each case, such Claims do not arise from the negligence or wilful default of the ZOGENIX Parties. For the avoidance of
doubt DESITIN shall in no event be liable for any claims arising from or in connection with the infringement of Third Party Rights, particularly patents and trademarks, caused by the manufacture or composition of the Product or the use of the
Trademark. 
  

	14.3	Each Party shall promptly provide the other Party with copies of all papers and official documents received in respect of any Claims and shall cooperate as
reasonably requested by the other Party in the defence of any Claims. The Party which is indemnifying the other Party hereunder shall have control of, and discretion in, the handling of the defense and/or settlement of any such Claim, including,
without limitation, the selection of defense counsel; provided, however, that the indemnified Party may take any appropriate action necessary to preserve or avoid prejudice to its interests, or the interests of the indemnifying Party, in the event
that (1) notice to the indemnifying Party cannot be given in sufficient time for such Party to take action, or (2) the indemnifying Party, after prompt notice and inquiry from the indemnified Party, fails to acknowledge its obligation to
indemnify the indemnified Party under this Clause 14. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 21

  

	14.4	Each Party shall maintain, at its own cost, comprehensive product liability insurance and general commercial liability insurance adequate to cover their
respective obligations under this Agreement in such amount as the Parties customarily maintain with respect to its other products and which is reasonable and customary in the pharmaceutical industry in their respective territories for companies of
comparable size and activities. Each Party shall maintain such insurance policy for not less than [***] ([***]) years following the expiry or termination of this Agreement. A certificate of insurance and any other documentation necessary to prove
compliance with this provision will be provided to the other Party upon request. 

  

	14.5	TO THE FULL EXTENT PERMITTED BY LAW, APART FROM THE FOREGOING WARRANTIES AND INDEMNITY OR SUCH WARRANTIES OR INDEMNITY AS MAY BE CONTAINED WITHIN THE
MANUFACTURING AGREEMENT, NEITHER PARTY MAKES ANY ADDITIONAL REPRESENTATIONS OR WARRANTIES AND HEREBY DISCLAIMS ALL WARRANTIES, REPRESENTATIONS, AND LIABILITIES, WHETHER EXPRESS OR IMPLIED, ARISING FROM CONTRACT OR TORT (EXCEPT FRAUD), IMPOSED BY
STATUTE OR OTHERWISE, RELATING TO THE PRODUCTS AND/OR ANY LICENSED TECHNOLOGY, INCLUDING ANY WARRANTIES AS TO MERCHANTABILITY, FITNESS FOR PURPOSE, CORRESPONDENCE WITH DESCRIPTION, OR NON-INFRINGEMENT. 

 

	14.6	IN NO EVENT WILL EITHER PARTY BE LIABLE FOR CONSEQUENTIAL, INCIDENTAL OR SPECIAL DAMAGES, INCLUDING ANY LOSS OF PROFITS, EVEN IF THE OTHER PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES. 

  

	15.	IMPROVEMENTS AND PATENTS 

  

	15.1	All right, title and interest in any Intellectual Property Right created, generated or arising in connection with the Product and any Improvement thereof,
whether invented solely by ZOGENIX, DESITIN or jointly by the Parties, shall be solely owned by ZOGENIX. 

  

	15.2	Each Party shall promptly disclose to the other any Improvements developed during the Term, and all such Improvements shall be deemed to the fullest extent
possible to be works made for hire exclusively for ZOGENIX, with ZOGENIX having sole ownership of such Improvements and the sole right to obtain and to hold in its own name patents, copyrights, or such other protection as ZOGENIX may deem
appropriate to the subject matter, and any extensions or renewals thereof (though ZOGENIX is under no obligation to file any patent application, secure or maintain any patent or register any copyright). To the extent DESITIN or its Affiliates
nonetheless maintain any rights in and to any Improvements, DESITIN and its Affiliates hereby assign, cede and grant to ZOGENIX all rights to possession of, and all right, title, and interest, including all patents and copyrights and the right to
prepare and exploit derivative works, in such Improvements. DESITIN agrees to give ZOGENIX or any person designated by ZOGENIX at ZOGENIX’s expense, all assistance reasonably required to perfect the rights hereinabove defined, including the
execution of documents and assistance or cooperation in legal proceedings. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 22

  

	15.3	In the event that either Party identifies any Third Party Intellectual Property Rights that in such Parties’ reasonably opinion would provide a commercial
benefit to the Product, it shall promptly inform the Other Party of such Intellectual Property Rights through the SC and the Parties shall in good faith discuss whether they intend to license or acquire such Third Party rights. In the event a
license in such Third Party Intellectual Property Right shall be taken, ZOGENIX shall negotiate and enter into such license including the right to sub-license its rights to DESITIN. Any sublicense of rights shall be set forth in a separate
sub-license agreement to be entered into between DESITIN and ZOGENIX and shall include terms substantially similar to those contained in this Agreement; provided that DESITIN and ZOGENIX shall equally share all Third Party license fees incurred.

  

	15.4	ZOGENIX shall, at its sole cost and expense, using patent attorneys of its choice, use Reasonable Commercial Efforts to file, prosecute and maintain the patents,
patent obligations and other Intellectual Property Rights related to the Licensed Technology in the Territory. Any costs relating to the filing of these Intellectual Property Rights in the Territory shall be borne by ZOGENIX.

  

	15.5	ZOGENIX shall, at its sole cost and expense, using trademark attorneys of its choice, use Reasonable Commercial Efforts to file, prosecute, maintain and enforce
the Trademark in the Territory. 

  

	16.	RIGHT OF FIRST REFUSAL 

  

	16.1	ZOGENIX hereby grants to DESITIN for the Term the right of first refusal to in-license any Product line extensions (including new or additional therapeutic uses)
which DESITIN desires to market in the Territory as set forth in this Clause 16 (the “ROFR”). 

  

	16.2	Following ZOGENIX’s decision to offer for license any Product line extension in the Territory, ZOGENIX shall promptly inform DESITIN in all relevant detail
of any such Product line extensions, thus giving DESITIN a meaningful basis for taking a decision on whether or not to exercise the ROFR. 

  

	16.3	For a period of no more than [***] ([***]) months after ZOGENIX has supplied DESITIN with the information referred to in Clause 16.2 (the “Review
Period”) DESITIN may exercise the ROFR by providing written notice to ZOGENIX within the Review Period of DESITIN’s desire to exercise the ROFR. The Parties shall thereafter negotiate in good faith for a period of no longer than [***]
([***]) additional months, the terms and conditions on which such Product line extension would be included within this Agreement, if at all. If the Parties are unable to reach agreement following the expiration of such additional [***] ([***])-month
period, ZOGENIX shall thereafter be permitted to license any such Product line extension to a Third Party on terms no more favourable to such Third Party than those most recently offered by DESITIN. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 23

  

	17.	REGULATORY 

  

	17.1	DESITIN shall, at its sole cost, use Reasonable Commercial Efforts (without being required to use all available resources) to prepare, file, prosecute and
maintain the Marketing Authorisations and other permits required for the commercialisation of the Product in the Territory. 

  

	17.2	Each Marketing Authorisation will be registered in DESITIN’s name. 

 

	17.3	DESITIN shall act as ZOGENIX’s consultant and representative towards the MOH and the other relevant authorities or third parties in connection with
obtaining and maintaining the Marketing Authorisation for the Product in the Territory. 

  

	17.4	ZOGENIX undertakes and covenants to DESITIN that it will not during the Term apply for an additional Marketing Authorisation relating to the Product in the
Territory nor will ZOGENIX during the Term apply for or otherwise seek the benefit of any substitute of the Marketing Authorisation. 

  

	17.5	ZOGENIX shall keep DESITIN fully informed of any changes to the Product which it reasonably believes might be relevant in relation to the Marketing
Authorisation. ZOGENIX shall not discontinue the supply of the Product containing the previous specifications unless all requirements set by a Regulatory Authority in the Territory for the maintenance or the renewal of the Marketing Authorisation
issued by it have been complied with. 

  

	17.6	DESITIN shall be responsible, as the case may be, for obtaining reimbursement for the Product on behalf of ZOGENIX in the Territory. ZOGENIX shall assist DESITIN
in obtaining reimbursement by providing all reasonable support and all Data as may be required by the relevant Regulatory Authority. 

  

	18.	PHARMACOVIGILANCE 

  

	18.1	The Parties shall use Reasonable Commercial Efforts to sign the Pharmacovigilance Agreement no later than [***] ([***]) months prior to the anticipated first
Launch of the Product in the Territory. 

  

	18.2	If there is any inconsistency between this Agreement and the Pharmacovigilance Agreement the terms of this Agreement will prevail between the Parties to the
extent of such inconsistency. 

  

	19.	EXCHANGE OF INFORMATION 

  

	19.1	DESITIN shall use the Dossier only during the Term and in furtherance of its rights and obligations under this Agreement. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 24

  

	19.2	DESITIN undertakes to neither sell nor otherwise make available to any Third Party the Dossier or any part thereof without a previous written approval from
ZOGENIX. 

  

	19.3	ZOGENIX will inform DESITIN promptly if the competent Regulatory Authority or any other competent authority gives notice to ZOGENIX or its Affiliates of any
difficulties or delays regarding the grant of the Marketing Authorisation in the U.S.A. or of any further studies to be conducted by ZOGENIX to obtain Marketing Authorisation in the U.S.A. 

 

	20.	[Intentionally Omitted] 

  

	21.	TERM AND TERMINATION 

  

	21.1	The term of this Agreement will continue on a country-by-country basis until the greater of ten (10) years after the Launch or the expiration in such country of
the last to expire Patent Right included in the Licensed Technology or Improvements licensed hereunder (the “Initial Term”). 

  

	21.2	After the Initial Term and only with respect to countries of the Territory where the Product has been successfully Launched, this Agreement shall be
automatically renewed on a country-by-country basis by additional successive periods of [***] ([***]) years unless it is terminated by either Party giving [***] ([***]) month’s prior written notice. 

 

	21.3	Either Party shall be entitled to terminate the Agreement if: 

  

	 	(a)	the other Party commits a material breach under this Agreement and in the case of a breach which is capable of remedy fails to remedy it within [***] ([***]) days of
receipt of notice from the first Party of such breach and of its intention to exercise its rights under this Clause; 

  

	 	(b)	the other Party enters into insolvency or bankruptcy or is unable to pay its debts as they fall due, or a trustee or receiver or the equivalent is appointed to the
other Party, or proceedings are instituted against the other Party relating to dissolution, liquidation, winding up, bankruptcy, insolvency or the relief of creditors, if such proceedings are not terminated or discharged within [***] ([***]) days;

  

	 	(c)	any law, decree, or regulation is enacted within the Territory which would substantially impair or restrict (1) the terminating Party’s right to terminate or
elect not to renew this Agreement as herein provided; (2) ZOGENIX’s right, title or interest in the Products or the Intellectual Property Rights therein; (3) as to DESITIN, DESITIN’s right to market and distribute the Products in
accordance with this Agreement; or (4) as to ZOGENIX, ZOGENIX’s right to collect the Purchase Price or Royalties as set forth in this Agreement; or 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 25

  

	 	(d)	an adverse event occurs which has substantially impaired the other Party’s ability to continue to perform its obligations hereunder and the other Party is unable
to provide the terminating Party with adequate assurance of future performance. 

  

	21.4	Either Party shall be entitled to terminate this Agreement with [***] ([***]) days written notice without any damage, legal redress or compensation due it if the
continued development or marketing of the Product is no longer possible due to advice from a relevant Regulatory Authority or clinical review board in the Territory or due to serious adverse events caused by the Product anywhere in the world.

  

	21.5	DESITIN shall be entitled to immediately terminate this Agreement with written notice and without any damage, legal redress or compensation due to ZOGENIX in
case: 

  

	 	(a)	a competent Regulatory Authority imposes therapeutic indications in the Territory not acceptable to DESITIN or require the Product to be marketed as generic drug in the
Territory; or 

  

	 	(b)	the Regulatory Authorities in the Territory require more than one study regarding bioequivalence of the Product to obtain Marketing Authorisation.

  

	21.6	ZOGENIX shall be entitled to terminate this Agreement with thirty (30) days written notice without any damage, legal redress or compensation due to DESITIN
in case: 

  

	 	(a)	 DESITIN in each of
[***] consecutive calendar years (other than any partial
calendar year in which the Product is first Launched) fails to meet at least [***]% of the mutually agreed sales forecasts provided that such shortfall is caused by circumstances within DESITIN’s reasonable control;

  

	 	(b)	DESITIN takes any act or step impairing the Intellectual Property Rights of ZOGENIX or does anything that might otherwise adversely affect the Intellectual Property
rights of ZOGENIX (whether DESITIN’s act or challenge of ZOGENIX’s rights is in good faith) and, if the act or step is capable of remedy, fails to remedy it within thirty (30) days of receipt of notice from ZOGENIX of such act or step
and of its intention to exercise its rights under this Clause 21.6; or 

  

	 	(c)	DESITIN ceases to carry on business in the marketing of pharmaceutical products in the Territory. 

 

	21.7	DESITIN shall be entitled to terminate this Agreement with [***] ([***]) days’ prior written notice under the conditions set forth in Section 8.1.
Following the effective date of such termination, ZOGENIX shall reimburse DESITIN for [***] percent ([***]%) of the Third Party costs incurred by DESITIN in connection with clinical development and regulatory approval of the Product in the Territory
under this Agreement, upon receipt of reasonably detailed documentation supporting such costs and such other supporting documentation as ZOGENIX may reasonably request. In no event shall the amounts reimbursed DESITIN pursuant to this
Section 21.7 exceed US$[***]. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 26

  

	22.	CONSEQUENCES OF TERMINATION 

  

	22.1	On expiration or termination of the Agreement for any reason whatsoever, the License granted under this Agreement shall cease and DESITIN shall, and shall
procure that its Affiliates and permitted sub-licensees shall: 

  

	 	(a)	Cease to carry out any of the activities permitted by this Agreement (or any relevant sub-license agreement) and cease to use or exploit in any way the Licensed
Technology; 

  

	 	(b)	Refrain from using the Trademark; and 

  

	 	(c)	Continue to treat the Licensed Know-how and any other information provided by ZOGENIX as secret and confidential according to Clause 23 hereof.

 In addition, on expiration of the Agreement or termination of the Agreement by ZOGENIX pursuant to Clauses 21.3
or 21.6, DESITIN shall grant to ZOGENIX a perpetual, royalty free license to use any trademark which DESITIN used in the commercialization of the Product in the Territory in connection with subsequent commercialization of the Product in the
Territory by or on behalf of ZOGENIX; provided, however, that such license shall not include a right for ZOGENIX to use the word DESITIN in any subsequent commercialization of the Product in the Territory. 

 

	22.2	DESITIN, its Affiliates and its permitted sub-licensees shall be entitled to continue to sell existing stocks of the Product in the Territory for a period of no
longer than [***]([***]) months following the date of termination, provided that DESITIN pays ZOGENIX any Royalty payments due in respect of such sales in accordance with the provisions of this Agreement. 

 

	22.3	The termination or expiry of this Agreement shall not release either of the Parties from any liability which at the time of termination or expiry has already
accrued to the other Party, nor affect in any way the survival of any other right, duty or obligation of the Parties which is expressly stated elsewhere in this Agreement to survive such termination or expiry. 

 

	23.	CONFIDENTIALITY 

  

	23.1	The Parties, their Affiliates and their respective employees, directors, officers, consultants and contractors shall keep and maintain as confidential any
Confidential Information supplied by the other Party prior to the Effective Date or during the Term. The confidentiality and non-disclosure obligations contained in this Agreement shall not apply to the extent that such Confidential Information is:

  

	 	(a)	at the time of disclosure by one Party to the other, in the public domain or otherwise publicly known; 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 27

  

	 	(b)	after disclosure by one Party to the other becomes part of the public domain, other than by breach of any obligation of confidentiality; 

 

	 	(c)	information which the receiving Party can establish by documentary evidence was already in its possession at the time of receipt or was independently developed by the
receiving Party; or 

  

	 	(d)	received from a Third Party who was lawfully entitled to disclose such information. 

 

	23.2	Notwithstanding clause 23.1, the Party receiving Confidential Information may disclose such Confidential Information: 

 

	 	(a)	to governmental or other regulatory agencies in order to file patent applications or prosecute such applications to grant, provided that, the disclosure is limited to
the extent reasonably required; provided that this sub-clause (a) shall only be applicable to Confidential Information of DESITIN received by ZOGENIX as it relates to Licensed Technology; or 

 

	 	(b)	to government or other Regulatory Authorities in order to file or prosecute any applications for Marketing Authorisations or other permits reasonably required to
research, develop, manufacture, use, distribution, sale or supply the Licensed Product, provided that the disclosure is limited to the extent reasonably required and is consistent with the rights of the Party under this Agreement; or

  

	 	(c)	to the extent that such disclosure has been ordered by a court of law or directed by a governmental body or authority in an enforceable decision, provided that, the
Confidential Information may be disclosed only to the extent so ordered or directed and wherever practicable, the Party that owns the Confidential Information has been given sufficient written notice in advance to enable it to seek protection or
confidential treatment of such Confidential Information. 

  

	23.3	Neither Party shall disclose any information about this Agreement without the prior written consent of the other. However, the Parties intend to announce the
execution and delivery of this Agreement promptly following such execution and delivery pursuant to the form of press release attached to this Agreement as Exhibit 23.3. Consent shall not be required, however, for (a) disclosures to tax
authorities or to bona fide potential sub-licensees, to the extent required or contemplated by this Agreement, provided, that in connection with such disclosure, each Party agrees to use its commercially reasonable efforts to secure confidential
treatment of such information; (b) disclosures of information for which written consent has previously been obtained, or (c) information which had previously been publicly disclosed, including pursuant to the press release described above.
Each Party shall have the further right to disclose the terms of this Agreement as required by applicable law, including the rules and regulations promulgated by the Securities and Exchange Commission and/or the regulatory bodies/authorities
governing securities issues in foreign jurisdictions and to disclose such information to stockholders or potential investors as is customary, provided the disclosing Party provides to the other Party, to the extent practicable, a copy of the
information to be disclosed and an opportunity to comment thereon prior to such disclosure, and, to the extent practicable, consults within a reasonable time in advance of the proposed disclosure with the other on the necessity for the disclosure
and the text of the proposed release. Any copy of this Agreement to be filed with the Securities and Exchange Commission shall be redacted to the reasonable satisfaction of both Parties; provided, however, in the event that the Securities and
Exchange Commission objects to the redaction of any portion of the Agreement after the initial submission, the filing Party shall inform the other Party of the objections and shall in good faith respond to the objections in an effort to limit the
disclosure required by the Securities and Exchange Agreement, but in any event the filing Party shall be free to include any portions of the Agreement it deems necessary to respond to the objections in any future filings. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 28

  

	24.	REPRESENTATIONS AND WARRANTIES 

  

	24.1	ZOGENIX and DESITIN each warrant that, as of the Effective Date: 

  

	 	(a)	it is a company duly organised and existing and has the power and authority to enter into this Agreement; 

 

	 	(b)	it has obtained all corporate authorisations required to enter into and perform its obligations under this Agreement; 

 

	 	(c)	there are no agreements between it and any Third Party that conflict with this Agreement; 

 

	 	(d)	no consent, approval, authorization or order of any court or governmental agency or body or Third Party is required for the execution and delivery by it of this
Agreement; 

  

	 	(e)	it has all rights necessary to perform its obligations under this Agreement, including the grant of rights by ZOGENIX hereunder; and 

 

	 	(f)	this Agreement is valid and binding obligation enforceable against it in accordance with its terms and conditions. 

 

	24.2	ZOGENIX warrants that, as of the Effective Date: 

  

	 	(a)	to the best of ZOGENIX’s knowledge, the sale and use of the Product does not infringe the Intellectual Property Rights of any Third Parties in the Territory and no
court proceedings or other proceeding for infringement of Intellectual Property rights have been brought against ZOGENIX with respect to the Product in the Territory; 

 

	 	(b)	to the best of ZOGENIX’s knowledge, no Third Party is infringing or has infringed any of ZOGENIX’s Intellectual Property Rights in the Licensed Technology in
the Territory or has misappropriated any of the Licensed Know How in the Territory. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 29

  

	25.	FORCE MAJEURE 

  

	25.1	Neither Party shall be entitled to terminate this Agreement or shall be liable to the other under this Agreement for loss or damages attributable to any Force
Majeure, provided the Party affected shall give prompt notice thereof to the other Party. The Party giving such notice shall be excused from such of its obligations hereunder for so long as it continues to be affected by Force Majeure.

  

	25.2	 If such Force Majeure continues unabated for a period of at least [***]
([***]) days, the Parties will meet to discuss in good
faith what actions to take or what modifications should be made to this Agreement as a consequence of such Force Majeure in order to alleviate its consequences on the affected Party. 

 

	26.	NOTICES 

  

	26.1	Any notice or other document given under this Agreement shall be in writing in the English language and shall be given by hand or sent by internationally
recognized overnight courier, by fax transmission to the address of the receiving Party as set out in Clause 26.3 below unless a different address or fax number has been notified to the other in writing for this purpose. 

 

	26.2	Each such notice or document shall: 

  

	 	(a)	if given by hand, be deemed to have been given when delivered at the relevant address; 

 

	 	(b)	if sent by internationally recognized overnight courier, be deemed to have been given two (2) Business Days following delivery to such overnight courier; and

  

	 	(b)	if sent by fax transmission, be deemed to have been given when transmitted provided that a confirmatory copy of such facsimile transmission shall have been given by
hand or sent by internationally recognized overnight courier as set forth herein. 

  

	26.3	The address for services of notices and other documents on the Parties shall be: 

 

									
	To DESITIN	 		 	To ZOGENIX
					
	Name:	 	Desitin Arzneimittel GmbH	 		 	Name:	 	Zogenix, Inc.
	Attn.:	 	Dr. Martin Zentgraf	 		 	Attn.:	 	Chief Financial Officer
	 Address:
	 	 Weg beim Jänger 214
 22335
Hamburg, Germany
	 		 	 Address:
	 	 11682 El Camino Real
 Suite
320
 San Diego, CA 92130, USA

	Fax:	 	0049 40 59 101 366	 		 	Fax:	 	001 858 259 1166
	E-Mail:	 	zentgraf@desitin.de	 		 	E-Mail:	 	dnassif@zogenix.com

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 30

  

	27.	ASSIGNMENT 

  

	27.1	Neither Party shall assign any of its rights or obligations under this Agreement to a Third Party without the prior written consent of the other, such consent
not to be unreasonably withheld, conditioned or delayed. ZOGENIX may assign its rights and obligations under this Agreement, without the prior written consent of DESITIN, to any Third Party purchaser of all or substantially all of the assets or
business to which this Agreement relates. 

  

	27.2	Either Party may at any time assign any of its rights under this Agreement to an Affiliate, provided however, that such Party remains fully liable for the
performance of such Party’s obligations hereunder by such Affiliate; provided further that any rights assigned by DESITIN to an Affiliate shall be immediately reassigned to DESITIN or assigned to an Affiliate of DESITIN if the assignee ceases
to be an Affiliate. 

  

	27.3	Either Party may at any time engage a contract research organisation to manage any non-clinical or clinical studies required under or in connection with the
Marketing Authorisation process. 

  

	27.4	Any assignment in violation of this Clause 27 shall be null and void. This Agreement shall be binding on and shall inure to the benefit of the permitted
successors and assigns of the Parties hereto. 

  

	28.	GENERAL PROVISIONS 

  

	28.1	The relationship of ZOGENIX and DESITIN established by this Agreement is of independent contractors, and nothing in this Agreement shall be construed:
(1) to give either Party the power to direct or control the daily activities of the other Party, or (2) to constitute the Parties as principal and agent, partners, or otherwise as participants in a joint undertaking. ZOGENIX shall have no
obligation or authority, express or implied, to exercise any control whatsoever over the employees or the business affairs of DESITIN. Except as specifically provided in this Agreement, DESITIN shall have no power or authority to make or give any
representation or warranty or to incur any liability or obligation, or to waive any right, on ZOGENIX’s behalf. 

  

	28.2	Each of the Parties shall do execute and perform all such further acts, deeds documents and things as the other Party may reasonably require from time to time to
give full effect to the terms of this Agreement. 

  

	28.3	Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and completion of this Agreement.

  

	28.4	This Agreement, its schedules and the agreements contemplated herein (particularly the Pharmacovigilance Agreement and the Manufacturing Agreement) set out the
entire agreement and understanding between the Parties in respect of the subject matter of this Agreement and supersede any heads of agreement which shall cease to have any further force or effect. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 31

  

	28.5	No variation of this Agreement, including this Clause 28.5, shall be valid unless it is in writing and signed by or on behalf of both Parties.

  

	28.6	If and to the extent that any provision of this Agreement is held to be illegal, void or unenforceable, such provision shall be given no effect and shall be
deemed not to be included in this Agreement but without invalidating any of the remaining provisions of this Agreement. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 32

  

	28.7	This Agreement and the obligations of the Parties shall be governed by and construed in accordance with the substantive laws of England to the exclusion of the
United Nations Convention on the International Sale of Goods. 

  

							
	SIGNED for and by behalf of	 		  		 	
	DESITIN Arzneimittel GmbH	 	 /s/ Dr. Martin Zentgraf
	  		 	March 14 2008
		 	Dr. Martin Zentgraf	  		 	Date
		 	General Manager	  		 	
				
		 	 /s/ Dr. Harald Jainta
	  		 	March 14, 2008
		 	Dr. Harald Jainta	  		 	Date
		 	Director Business Development	  		 	
				
	SIGNED for and by behalf of	 		  		 	
	ZOGENIX, INC.	 	 /s/ Roger L. Hawley
	  		 	March 14, 2008
		 	Roger L. Hawley	  		 	Date
		 	CEO	  		 	

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 33

  

 Appendix 1 

PRODUCT SPECIFICATION 

sumatriptan DosePro is a sterile, pre-filled, single-use, disposable, needle-free subcutaneous delivery system delivering sumatriptan injection.
sumatriptan DosePro consists of the following components: a gray plastic handle and snap-off tip, a green lever, and a glass medication chamber that is pre-filled with 6 mg/0.5 mL sumatriptan injection. Utilizing pressure from a compressed nitrogen
gas source in the handle, sumatriptan DosePro delivers the medication by pushing it through a small, precise hole in the glass medication chamber. The resulting stream of medication is propelled through the skin and is delivered subcutaneously
without a needle, following a unique biphasic pressure profile. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 34

  

 Appendix 2 

LICENSED PATENTS 

[***] 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	 	 Page
 35

  

 Appendix 3 

Clinical Supply Terms 

Pursuant to the terms of this Appendix 3, ZOGENIX shall supply DESITIN with its requirements for Clinical Trial Materials solely for use
in clinical trial activities in the Territory in support of Marketing Authorisation for the Product in the Territory (“Development”). Clinical Trial Materials supplied by ZOGENIX shall be provided at the prices set forth in Clause 8 of the
Agreement or at such other transfer prices as the parties may mutually agree. 
 DESITIN shall place its first order for
Clinical Trial Materials no later than [***] ([***]) months following the Effective Date, to be delivered no later than additional [***] ([***]) months thereafter. DESITIN shall place subsequent orders for Clinical Trial Materials at least [***]
([***]) months prior to the desired delivery date. ZOGENIX will use Reasonable Commercial Efforts to meet DESITIN’s requested quantities and delivery dates. ZOGENIX shall notify DESITIN of the specific delivery date and quantity for each
subsequent order no later than [***] ([***]) months following receipt of DESITIN’s order by ZOGENIX. 
 DESITIN
acknowledges and agrees that ZOGENIX will manufacture Clinical Trial Materials or will enter into a contractual relationship with one or several manufacturers for the Clinical Trial Materials. Such Third Party manufacturers shall manufacture
Clinical Trial Materials on ZOGENIX’s behalf in accordance with applicable law in the Territory. 
 Any Clinical Trial
Materials supplied by ZOGENIX hereunder shall be manufactured: (a) in accordance with cGMP; (b) in compliance with the Product Specification; and (c) in compliance with all applicable and relevant national and local laws, rules and
regulations, including those promulgated by any relevant Regulatory Authority. 
 Clinical Trial Materials shall be supplied by
ZOGENIX to DESITIN as finished products ready for final packing and labelling as required in each country of the Territory (DESITIN will be responsible for such items as set forth in Clause 7.3 of the Agreement as well as quality control, in each
case at its own expense). Each shipment of Clinical Trial Materials shall be accompanied by the corresponding analytical certificate attesting to compliance with the Product Specification. Clinical Trial Materials shall be placed at DESITIN’s
disposal EXW (Incoterms 2000) ZOGENIX’s manufacturing facility. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

			
	Licensing & Distribution Agreement between Zogenix & Desitin as of March 14, 2008	  	 Page
 36

  

 Exhibit 23.3 

Form of Press ReleaseManufacturing Services Agreement

 Exhibit 10.18 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
 Manufacturing Services Agreement

 Between 

Patheon UK Limited 

And 

Zogenix Inc. 

1st November, 2008 

 Table of Contents 

 

					
		 		  	
	 ARTICLE 1
	 		  	- 2 -
	 INTERPRETATION
	  	- 2 -
	 1.1
	 	Definitions.	  	- 2 -
	 1.2
	 	Currency.	  	- 6 -
	 1.3
	 	Sections and Headings.	  	- 7 -
	 1.4
	 	Singular Terms.	  	- 7 -
	 1.5
	 	Schedules.	  	- 7 -
	 ARTICLE 2
	 		  	- 8 -
	 PATHEON’S OBLIGATIONS
	  	- 8 -
	 2.1
	 	Manufacturing and Support Services.	  	- 8 -
	 2.2
	 	Standard of Performance.	  	- 11 -
	 ARTICLE 3
	 		  	- 12 -
	 ZOGENIX’S OBLIGATIONS
	  	- 12 -
	 3.1
	 	Payment.	  	- 12 -
	 3.2
	 	Materials.	  	- 12 -
	 3.3
	 	Exclusivity.	  	- 12 -
	 3.4
	 	Import and Export Matters.	  	- 13 -
	 3.5
	 	Specifications.	  	- 13 -
	 ARTICLE 4
	 		  	- 14 -
	 SERVICE AND SUPPORT FEES, TIERED PRICING
	  	- 14 -
	 4.1
	 	Fees for Manufacturing and Support Services.	  	- 14 -
	 4.2
	 	Adjustments to Year’s Pricing.	  	- 14 -
	 4.3
	 	Adjustments Due to Technical Changes.	  	- 15 -
	 4.4
	 	Multiple Packaging Formats.	  	- 15 -
	 4.5
	 	Pricing Assumptions.	  	- 15 -
	 4.6
	 	Taxes.	  	- 15 -
	 4.7
	 	Tiered Pricing.	  	- 15 -
	 ARTICLE 5
	 		  	- 16 -
	 ORDERS, DELIVERY, INVOICING, PAYMENT, MINIMUM VOLUMES, PRODUCT DEFICIENCIES
	  	- 16 -
	 5.1
	 	Market Outlook.	  	- 16 -
	 5.2
	 	Orders and Forecasts.	  	- 16 -
	 5.3
	 	Reliance by Patheon.	  	- 17 -
	 5.4
	 	Order Size.	  	- 18 -
	 5.5
	 	Rental of Manufacturing Space.	  	- 18 -
	 5.6
	 	Delivery.	  	- 19 -
	 5.7
	 	Invoices and Payment for Service Fees.	  	- 19 -
	 5.8
	 	Invoices and Payment for Support Fees.	  	- 20 -

  

 - i - 

					
	 5.9
	 	Invoices and Payment for Rental of Manufacturing Space.	  	- 20 -
	 5.10
	 	Product Deficiencies.	  	- 20 -
	 ARTICLE 6
	 		  	- 22 -
	 CO-OPERATION
	  	- 22 -
	 6.1
	 	Joint Steering Committee.	  	- 22 -
	 6.2
	 	Product Recalls.	  	- 23 -
	 6.3
	 	Governmental Agencies.	  	- 23 -
	 6.4
	 	Records and Accounting by Patheon.	  	- 23 -
	 6.5
	 	Access, Person in Plant.	  	- 24 -
	 6.6
	 	Subordination and Waiver Agreement.	  	- 24 -
	 6.7
	 	Relationship Manager.	  	- 24 -
	 ARTICLE 7
	 		  	- 25 -
	 TERM AND TERMINATION
	  	- 25 -
	 7.1
	 	Term.	  	- 25 -
	 7.2
	 	Termination for Cause.	  	- 25 -
	 7.3
	 	Obligations on Termination.	  	- 26 -
	 ARTICLE 8
	 		  	- 28 -
	 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	- 28 -
	 8.1
	 	Authority.	  	- 28 -
	 8.2
	 	Covenants, Representations and Warranties.	  	- 28 -
	 8.3
	 	Permits.	  	- 29 -
	 8.4
	 	Compliance with Laws.	  	- 29 -
	 8.5
	 	Patheon Representations, Covenants and Limited Warranty.	  	- 29 -
	 ARTICLE 9
	 		  	- 31 -
	 REMEDIES AND INDEMNITIES
	  	- 31 -
	 9.1
	 	Consequential Damages.	  	- 31 -
	 9.2
	 	Limitation of Liability.	  	- 31 -
	 9.3
	 	Patheon.	  	- 32 -
	 9.4
	 	Zogenix.	  	- 32 -
	 ARTICLE 10
	 		  	- 34 -
	 CONFIDENTIALITY
	  	- 34 -
	 10.1
	 	Confidentiality.	  	- 34 -
	 10.2
	 	Confidential Information.	  	- 34 -
	 ARTICLE 11
	 		  	- 35 -
	 DISPUTE RESOLUTION
	  	- 35 -
	 11.1
	 	Commercial Disputes.	  	- 35 -
	 11.2
	 	Technical Dispute Resolution.	  	- 35 -
	 ARTICLE 12
	 		  	- 36 -
	 MISCELLANEOUS
	  	- 36 -
	 12.1
	 	Intellectual Property.	  	- 36 -
	 12.2
	 	Insurance.	  	- 36 -
	 12.3
	 	Independent Contractors.	  	- 36 -

 

 - ii - 

					
	 12.4
	 	No Waiver.	  	- 36 -
	 12.5
	 	Assignment.	  	- 37 -
	 12.6
	 	Force Majeure.	  	- 37 -
	 12.7
	 	Additional Product.	  	- 37 -
	 12.8
	 	Notices.	  	- 38 -
	 12.9
	 	Severability.	  	- 38 -
	 12.10
	 	Entire Agreement.	  	- 38 -
	 12.11
	 	No Third Party Benefit or Right.	  	- 39 -
	 12.12
	 	Execution.	  	- 39 -
	 12.13
	 	Governing Law.	  	- 39 -
	 12.14
	 	Resolution.	  	- 39 -
	 SCHEDULE A
	  	- 41 -
	 PRODUCTS, SERVICE FEES, PRICING ASSUMPTIONS, RENTAL FEES
	  	- 41 -
	 SCHEDULE B
	  	- 47 -
	 SUPPORT FEES
	  	- 47 -
	 SCHEDULE C
	  	- 51 -
	 MATERIALS
	  	- 51 -
	 SCHEDULE D
	  	- 52 -
	 EQUIPMENT
	  	- 52 -
	 SCHEDULE E
	  	- 57 -
	 FORECAST MODEL
	  	- 57 -
	 SCHEDULE F
	  	- 64 -
	 SUPPLY CHAIN TELECONFERENCES AND INVENTORY REPORT
	  	- 64 -

  

 - iii - 

 MANUFACTURING SERVICES AGREEMENT 

THIS MANUFACTURING SERVICES AGREEMENT (the “Agreement”) made as of this
1st day of November, 2008 

BETWEEN:- 
 PATHEON UK LIMITED, a
company with a registered office at Kingfisher Drive, Covingham, Swindon, Wiltshire, SN3 5BZ, incorporated under the laws of England, (hereinafter referred to as “Patheon” ), 

And 
 ZOGENIX INC, a company with a
registered office at 12671 High Bluff Drive, Suite 200, San Diego California, 92130, USA, incorporated under the laws of Delaware (hereinafter referred to as “Zogenix”). 

Each of Patheon and Zogenix being hereinafter referred to as a “Party” if individually considered and as “Parties” if jointly
considered. 
  

 - - 1 - - 

 THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations
assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows:- 

ARTICLE 1 

INTERPRETATION 
  

	1.1	Definitions. 

 The
following terms shall, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:- 

“Affiliate” means: 
  

	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise; or 

 

	 	(b)	a business entity which is owned by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or 

 

	 	(c)	a business entity, the majority ownership of which is directly or indirectly common to the majority ownership of a party to this Agreement; 

“Annual Stability Commitment” shall have the meaning ascribed in Quality Agreement; 

“Batch” shall mean a uniquely identified or identifiable quantity of Products that have been produced by one
(1) process or series of processes to the extent that such quantity could insofar be expected to be homogeneous. The meaning is as set forth in 21 C.F.R. §820; 

“Binding Letter Agreement” means the agreement relating to the employment of project staff between
Patheon and Zogenix dated 7th November 2006;

 “Breach Notice” shall have the meaning ascribed in Section 7.2(a); 

“Break Fee” shall have the meaning ascribed in Section 7.3(d); 

“Business Day” means a day other than a Saturday, Sunday or a day that is a statutory holiday in the United Kingdom and
in the United States of America; 
 “cGMP” means current Good Manufacturing Practice published by the European
Commission in the “Guide to good manufacturing practice for medicinal products” (“The rules governing medicinal products for human use”, IV Volume), as specified by the competent Regulatory Authorities, and 21
C.F.R. § 211, and FDA guidance pertaining thereto; 
  

 - - 2 - - 

 “Capacity” shall mean the quantity of Product Patheon is able to produce
from the Facility during a defined period of time based on the assumptions set out in Schedule A, which may be amended in writing from time to time as agreed between the parties; 

“Claim(s)” shall have the meaning ascribed in Section 9.3; 

“Confidentiality Agreement” means the Mutual Non Disclosure agreement relating to the non-disclosure
of confidential information between Patheon and Zogenix dated
18th September 2006; 

“Conversion Fee” shall have the meaning ascribed in Schedule A attached hereto as amended between the Parties from time
to time. 
 “Deed” shall mean the Deed of Subordination and Waiver under which Zogenix has securitised its
assets with the General Electric Capital Corporation dated as of March 5, 2007 and updated on December 27, 2007 (“the Deed”) and the Parties to this Agreement agree that all matters in relation to Equipment covered by the Deed
shall be subject to its terms and conditions. 
 “Deficiency Notice” shall have the meaning ascribed thereto in
Section 5.9(a); 
 “Effective Date” means the
1st day of November 2008; 

“Equipment” shall mean all the equipment listed in Schedule D attached hereto as well as any other manufacturing or
inspection equipment owned by Zogenix (or provided by any third party for the benefit of Zogenix) that is used for the fulfilment of the Manufacturing Services hereunder; 

“EXW” means “Ex works”, as that term is defined in INCOTERMS 2000; 

“Facility” means the manufacturing facility of Patheon, at Kingfisher Drive, Covingham, Swindon, Wiltshire, SN3 5BZ,
United Kingdom, and where manufacturing of the Products under this Agreement shall take place; 
 “FDA” means
the United States Food and Drug Administration; 
 “FDC Act” shall mean the United States Food, Drug &
Cosmetic Act, as amended from time to time, and the regulations promulgated pursuant thereto; 
 “Finished Pack”
means a finished pack of Product, as further described in Schedule A; 
 “Firm Orders” has the meaning specified
in Section 5.2(b); 
  

 - - 3 - - 

 “GE” shall have the meaning ascribed thereto in Section 6.6;

 “Improvements” shall mean all improving modifications or adaptations to any of the patents or know-how
relating to the Product, whether patentable or not, which might reasonably be of commercial interest to either party in the design, manufacture, supply or use of the Product and which may be made, acquired by or disclosed to Patheon or Zogenix
during the term of this Agreement; 
 “Initial Term” shall have the meaning ascribed thereto in
Section 7.1; 
 “Intellectual Property” includes, without limitation, rights in patents, patent
applications, formulae, trade-marks, trade-mark applications, trade-names, trade secrets, inventions, copyrights, industrial designs, know-how; 

“Inventory” means all inventories of Materials and work-in-process produced or held by Patheon in connection with the
manufacture of the Products; 
 “Manufacturing and Support Services” means the manufacturing, quality control,
quality assurance and stability testing, packaging and related services, as contemplated in this Agreement, either required to produce Products from the Materials or requested to be completed by Zogenix; 

“MA” means Marketing Authorisation pursuant to Directive 65/65 EEC (as amended by following provisions including
Directive 2001/83/EC) or any implementation of it or its equivalent under the laws of a relevant Member State, or the approved NDA or equivalent thereof; 

“Make Good Costs” means the reasonable costs required to repair the Facility and return it into a useable area based on a
“like for like” replacement of any damaged materials. 
 “Manufacturing Requirements” means
Patheon’s responsibilities and obligations with respect to the provision of Manufacturing Services as set forth in Article 2; 

“Materials” means the materials listed in Schedule C used in the manufacture of the Product; 

“Minimum Campaign Size” shall have the meaning ascribed in Schedule A; 

“MRP” shall mean Materials Requirements Planning; 

“NDA” means New Drug Application under Section 505 of the Federal Food Drug and Cosmetic Act, by the FDA;

  

 - - 4 - - 

 “Occupancy Agreement” shall mean the Occupancy Charge,
Industrialisation and Project Agreement between Patheon and Zogenix dated
27th March 2007, the First Amending Agreement to the
Occupancy Agreement dated 1st August 2007 and the
Annex to the Occupancy Agreement dated 1st September
2007; 
 “Pricing Assumptions” shall have the meaning ascribed thereto in Schedule A; 

“Product(s)” means the products listed on Schedule A hereto; 

“Product Quality Review” shall have the meaning ascribed thereto in Section 2.1(f); 

“Quality Agreement” means the agreement relating to pharmaceutical quality agreed between the parties
with an effective date of 1st November 2008;

 “Regulatory or Government Authority” shall mean, with respect to the United States, the U.S. Food and Drug
Administration (“FDA”), or any equivalent foreign regulatory authority or applicable agency; 
 “Remediation
Period” shall have the meaning ascribed in Section7.2(a); 
 “Service Fee” means the fees set out in
Schedule A covering the cost of Materials purchased by Patheon and the conversion of Materials into Product; 
 “Shift
Pattern A” shall have the meaning ascribed in table A-1 of Schedule A; 
 “Shift Pattern B” shall have
the meaning ascribed in table A-1 of Schedule A; 
 “Shift Pattern C” shall have the meaning ascribed in table
A-1 of Schedule A; 
 “Shift Pattern D” shall have the meaning ascribed in table A-1 of Schedule A; 

“Specifications” means the file, for each Product, which is provided by Zogenix to Patheon and which contains documents
relating to such Product, including, without limitation: 
  

	 	(a)	written specifications for Materials and Product; 

  

	 	(b)	manufacturing and packaging process specifications; 

  

	 	(c)	shipping and storage requirements; 

  

 - - 5 - - 

	 	(e)	all environmental, health and safety information relating to the Product including material safety data sheets. all as updated, amended and revised from time to time by
Zogenix in accordance with the terms of the Agreement; and 

  

	 	(f)	any other technical information necessary to carry out the contracted operations correctly in accordance with the MA and any other legal requirements,

 all as updated, amended and revised from time to time by Zogenix in accordance with the terms of this Agreement;

 “Standard Batch Size” shall have the meaning ascribed in Schedule A; 

“Steering Committee” shall be the joint committee of which the details concerning representation and functions are set
out in Section 6.1; 
 “Support Fees” means the fees set out in Schedule B covering activities performed by
Patheon to support the registration of the Product. The Support Fees are in addition to the Service Fee for the Product; 

“Technical Dispute” has the meaning specified in Section 11.2; 

“Territory” means in the geographic area of the United States of America and all its territories and possessions and the
states of the European Union and any other geographic regions where Zogenix may elect to market the Product; 
 “Third
Party Rights” means the Intellectual Property of any third party; 
 “Unit” shall have the meaning
ascribed in Schedule A; 
 “Vendor Supply Agreement” means a commercial agreement between either Patheon or
Zogenix with the vendor of a Material covering the supply of such Material; 
 “Year” means the twelve
(12) month period commencing, in the case of the first Year of this Agreement, on the Effective Date, and thereafter commencing upon completion of the immediately preceding Year. 

 

	1.2	Currency. 

 Unless
otherwise indicated, all monetary amounts are expressed in this Agreement in Pounds Sterling (“GBP”). 
  

 - - 6 - - 

	1.3	Sections and Headings. 

The division of this Agreement into Articles, sections, subsections and Schedules and the insertion of headings are for convenience of
reference only and shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section or Schedule refers to the specified Section or Schedule to this Agreement. In this Agreement, the
terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement and not to any particular part, Section, Schedule or the provision hereof.

  

	1.4	Singular Terms. 

Except as otherwise expressly provided herein or unless the context otherwise requires, all references to the singular shall include the
plural and vice versa. 
  

	1.5	Schedules. 

 The
following Schedules are attached to, incorporated in and form part of this Agreement: 
  

					
	Schedule A	  	–	  	Products, Service Fees, Standard Batch Size, Minimum Campaign Quantity, Capacity
	Schedule B	  	 –
	  	Support Fees
	Schedule C	  	–	  	Materials and Services and Responsibility Matrix
	Schedule D	  	–	  	Zogenix Equipment and Equipment Maintenance and Repair
	Schedule E	  	–	  	Forecast Model
	Schedule F	  	–	  	Supply Chain Teleconferences and Inventory Reports

  

 - - 7 - - 

 ARTICLE 2 

PATHEON’S OBLIGATIONS 
  

	2.1	Manufacturing and Support Services. 

Patheon shall provide to Zogenix the Manufacturing and Support Services for the Territory for the fees specified in Schedules A and B in
order to produce Products for Zogenix. In providing the Manufacturing and Support Services: 
  

	 	(a)	Conversion of Materials. Patheon shall convert Materials into Product in accordance with the Specifications, the cost of such activities being included in the
Service Fee; 

  

	 	(b)	Quality Control and Quality Assurance. Patheon shall perform quality assurance and quality control testing for Materials and Products set out in the Quality
Agreement and Specifications, the cost of such activities being included in the Service Fee; 

  

	 	(c)	Materials. Patheon shall be responsible for implementing Vendor Supply Agreements (from those suppliers from whom it its Patheon’s responsibility to procure
Materials), ordering, receiving, making payment for and storing Materials as set in Schedule C; 

  

	 	(d)	Stability Testing. Patheon shall conduct stability testing on the Products in accordance with protocols provided by Zogenix. The cost of stability storage and
testing for [***] (the “Annual Stability Commitment” for the Product) shall be included in the Service Fee. Any stability testing requested by Zogenix over and above the Annual Stability Commitment shall be invoiced to Zogenix by
Patheon for the separate fees specified in Schedule B. In the event that any Batch of Products fails stability testing, Patheon and Zogenix shall jointly determine the proceedings and methods to be undertaken to investigate the causes of such
failure, including which party shall bear the cost of such investigation, provided that Patheon shall not be liable for any such costs unless there has been a failure by it to provide the Manufacturing and Support Services in accordance with the
Manufacturing Requirements. Patheon will provide any and all data and results relating to the stability testing annually as reasonably requested by Zogenix; 

 

	 	(e)	Support to Maintain Regulatory Filings. Patheon shall provide Zogenix with reasonable assistance and documentation necessary to keep the MA in effect and
necessary to respond to inquiries and requests from the FDA and other relevant regulatory authorities. Zogenix shall reimburse Patheon for such support services as set out in Schedule B; 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 8 - - 

	 	(f)	Product Quality Review. Patheon shall provide data to enable Zogenix to perform trending and critical analysis for the Product during each Year of the Agreement
(a “Product Quality Review”). The data relating to the Product to be provided by Patheon will be sufficient to allow Zogenix to fulfil its annual reporting obligations to the FDA and will include but not be limited to:

  

	 	(i)	Materials 

  

	 	(ii)	Critical in process control and finished product testing results 

  

	 	(iii)	Deviations and out of specifications 

  

	 	(iv)	Changes to Materials or the Product 

  

	 	(v)	Stability studies 

  

	 	(vi)	Complaints relating to the Product 

  

	 	(vii)	Corrective and preventive actions 

  

	 	(viii)	Qualification and validation of equipment and processes used in the manufacture of the Product 

 

	 	(ix)	Quality Agreement 

 hereinafter
collectively the “PQR Data”. 
 The cost of providing the PQR Data shall be included in the Service Fee. In the
event that Zogenix requests that Patheon provides data over and above the PQR Data or that Patheon perform trending and critical analysis on the PQR Data, then Zogenix shall reimburse Patheon for such services as set out in Schedule B; 

 

	 	(g)	Audit Support. Patheon shall provide, at no cost to Zogenix, support for [***] per annum by Zogenix of Patheon’s quality and compliance systems at the
Facility in accordance with the provisions set out in the Quality Agreement. In the event that Zogenix requests that Patheon provide support for more than [***] per annum at the Facility and such additional audits are not required to address
legitimate quality concerns and the Parties have not mutually agreed otherwise, Zogenix shall reimburse Patheon as set out in Schedule B. For the avoidance of doubt, audits by third parties of the Facility that are requested by Zogenix shall be
considered a Zogenix audit for the purposes of this Section. For the further avoidance of doubt, inspections by Regulatory or Governmental Authorities or due diligence visits by prospective licensees of the Product shall not be considered a quality
audit for the purposes of this Section; 

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 9 - - 

	 	(h)	Artwork Generation and Updates. Patheon shall coordinate the generation, approval and updates of artwork for printed packaging within Patheon’s internal
systems. For the avoidance of doubt, the generation of original artwork is the responsibility of Zogenix, with Patheon responsible for manipulating this artwork so that it complies with its internal processing requirements. Zogenix shall reimburse
Patheon for artwork generation and updates as set out in Schedule B; 

  

	 	(i)	Additional Sampling. Patheon shall take additional samples of Product or Materials upon request by Zogenix. For the avoidance of doubt, samples taken routinely
for Materials release testing, in process control, finished Product testing, retention samples held by Patheon as necessary to fulfil regulatory requirements or stability testing shall not be considered additional samples. Zogenix shall reimburse
Patheon for any additional sampling as set out in Schedule B; 

  

	 	(j)	Batch Record and Specification Update. Patheon shall generate and update Batch manufacturing records, Batch packaging records, Material testing specifications
and Product testing specifications as reasonably required. If updates to existing Batch manufacturing records, Batch packaging records, Material testing specifications and Product testing specifications are initiated by Zogenix, then Zogenix shall
reimburse Patheon as set out in Schedule B; 

  

	 	(k)	Additional Testing. Patheon shall perform additional testing on Materials or Product at the request of Zogenix. For the avoidance of doubt, any testing over and
above the standard in process or release testing for Materials or Product set out in the Specifications shall be considered additional testing. Zogenix shall reimburse Patheon for such additional testing as set out in Schedule B.

  

	 	(l)	Equipment Maintenance and Repair. Patheon shall be responsible for maintenance and repair of the Equipment in accordance with Schedule D attached hereto and for
the costs set out therein. 

  

	 	(m)	Process Optimisation and Project Activities. Patheon shall, where possible, recommend and, at the request of Zogenix, perform process optimisation, efficiency
and project activities relating to the Product. Zogenix shall reimburse Patheon for such optimisation and project activities as set out in Schedule B. 

  

	 	(n)	Additional Access. In addition to the access described in paragraph (g) above, Patheon shall allow reasonable access to third parties (by way of
illustration and not limitation, insurance agents or agents of Zogenix’ financiers) to the Facility as reasonably requested by Zogenix. However, it is understood and agreed that any such third parties must adhere and conform to all and any
Patheon health, safety or quality requirements whilst at the Facility. Patheon reserves the right to either refuse entry to or remove from the Facility any individual breaching such requirements. 

 

 - - 10 - - 

	2.2	Standard of Performance. 

Patheon represents and undertakes to Zogenix that it shall perform the Services in accordance with the MA, cGMPs (where relevant), any
other applicable legal requirements and in accordance with any instructions given by Zogenix, Regulatory or Governmental Authorities in connection with the Services. In addition, and without prejudice to anything else in this Agreement, Patheon
represents and undertakes to Zogenix that it shall perform the Services in accordance with reasonable skill, care and judgment; hereinafter collectively the “Manufacturing Requirements”. 

 

 - - 11 - - 

 ARTICLE 3 

ZOGENIX’S OBLIGATIONS 
  

	3.1	Payment. 

 Pursuant
to the terms of this Agreement, Zogenix shall pay Patheon for the provision of the Manufacturing and Support Services according to the fees specified in Schedules A and B hereto. 

 

	3.2	Materials. 

  

	 	(a)	Zogenix shall be responsible for implementing Vendor Supply Agreements, ordering, receiving, making payment for and storing Materials as set in Schedule C. Furthermore,
Zogenix shall be obliged to provide said Materials at the times and in the quantities required in order to allow Patheon to fulfil its obligations hereunder. 

 

	 	(b)	If Zogenix is unable to supply the Materials described in paragraph (a) and: (i) such inability to supply is not due to an event of force majeure as defined
in Section 12.6; and (ii) as a result, Patheon is unable to supply Firm Orders, it will be considered that Zogenix has cancelled these Firm Orders and the relevant provisions of Section 5.2(b) shall apply. Furthermore, if such
inability to supply the Materials continues for a period in excess of [***], then Patheon, at its sole discretion, may then apply the rental fee described in Section 5.5 until the time that Zogenix is able to resume supply of all such Materials
and Patheon is able to fulfil Firm Orders. 

  

	3.3	Exclusivity. 

Zogenix shall purchase [***] for all Products (including unidentified products yet to be developed that use the DoseProTM device and
are commercialized by Zogenix) from Patheon (or its Affiliates). In the event Zogenix wishes to license out or otherwise divest its interest in all or part of the Product or license out the use of the DoseProTM device for use with another
pharmaceutical product, the Parties hereby agree that, unless Patheon is unwilling or unable to do so, Zogenix shall recommend to such relevant third party the appointment of Patheon as the exclusive provider for any Manufacturing Services required.
In the event Patheon is unable to supply sufficient Product to Zogenix due to Patheon’s inability to supply or lack of available Capacity, then Zogenix has the right to use other suppliers until such time as Patheon is capable of fulfilling
Zogenix’ demands. In the event the required increase in Capacity needs additional capital investment, then the Parties shall discuss in good faith the allocation of costs and timelines associated therewith. In the absence of any good faith
agreement, Zogenix shall be entitled to obtain the additional Product above the existing Capacity from a third party without any obligation to Patheon. In addition, Patheon agrees not to enter into any other agreements with any third parties in
relation to the manufacture of any other needle free devices for the injection of liquids without the prior consent of Zogenix, such consent not to be unreasonably withheld. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 12 - - 

	3.4	Import and Export Matters. 

Zogenix shall, at its own expense, prepare, obtain and maintain all necessary import and export documentations and permits relating to the
Product. 
  

	3.5	Specifications. 

Zogenix is the design authority and will set all Specifications. Patheon is responsible for reviewing and providing input to the
Specifications. Specifications will be mutually agreed and included in the Quality Agreement. Any changes to agreed Specifications must be made under the change control systems of both companies. For the avoidance of doubt, Zogenix has the ultimate
responsibility and liability for the compliance and applicability of all Specifications. 
  

 - - 13 - - 

 ARTICLE 4 

SERVICE AND SUPPORT FEES, TIERED PRICING 
  

	4.1	Fees for Manufacturing and Support Services. 

The Support Fees listed in Schedule B are intended by the Parties to be fixed for the Term of this Agreement, subject
to the amendments provided for in this Article 4. The Service Fees listed in Schedule A are based on certain assumptions which require further information prior to being verified by the Parties. The Parties intend to fix the Service Fee for the Term
of this Agreement once sufficient information is available to mutually agree in good faith appropriate levels of tiered pricing. The Parties further agree that, by no later than the end of the first Year of this Agreement, such tiered pricing levels
shall be agreed (unless the Parties mutually agree to extend such period). In the event that no agreement has been reached by
September 1st, 2009 then the commercial dispute
resolution shall be applied as per Section 11.1 below. Once agreed such Service Fees shall be subject to the amendments to such fees provided for in this Article 4. 

 

	4.2	Adjustments to Year’s Pricing. 

During any period following the first anniversary of this Agreement, the Service Fee and Support Fees shall be subject to adjustment in
accordance with the following: 
  

	 	(a)	[***]. If [***]. To the extent that Service Fees have been previously adjusted pursuant to this Section 4.2(a) [***]. Such adjustment to the Service Fee shall be
effective [***]. 

  

	 	(b)	Support Fees, Conversion Fees and Rental Fees. On [***]. Such adjustment shall be effective as of [***]. 

 

	 	(c)	The parties may at any time propose initiatives to reduce cost. If such initiative is agreed to by both parties, then the benefits of any such initiative will be
applied first to enable the parties to recover any investment made to facilitate it, if any, and then shared between the parties in such proportions of the respective investments. 

In connection with a Service Fee, Support Fee or rental adjustment pursuant to this Section 4.2, Schedule A and/or Schedule B shall
be revised to reflect the updated [***]. At the request of Zogenix, Patheon shall provide documentation sufficient to demonstrate that such a fee adjustment is justified. 
  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 14 - - 

	4.3	Adjustments Due to Technical Changes. 

Amendments to the Manufacturing Requirements requested by Zogenix [***]: 

 

	 	(a)	[***]; 

  

	 	(b)	[***]; 

  

	 	(c)	[***]. 

 If [***]. 

The above provisions shall also apply if [***]. 
  

	4.4	Multiple Packaging Formats. 

If Zogenix requires Patheon to pack Product in a different format to that listed in the then current Schedule A, Patheon shall assess the
cost of producing the new pack format, taking into account factors including but not limited to pack size, packaging design, artwork design, cost of Materials, packing run size, then present Zogenix with a quotation on the Service Fee for the new
pack format. If Zogenix agrees to the Service Fee quotation for the new pack format, Schedule A shall be updated to include the quoted Service Fee for the new pack format. 

 

	4.5	Pricing Assumptions. 

Both Parties agree that the Capacity of the Equipment and area within the Facility used to manufacture the Product and the resource
required to achieve this level of output are critical assumptions for the calculation of pricing. The Service Fees for the Products will be based on the assumptions set out in Schedule A. In the event that these assumptions change, both parties will
be entitled to assess the impact of such changes on the cost of manufacturing the Product and negotiate a fair adjustment to the Service Fees. 
  

	4.6	Taxes. 

 The
Service Fees and Support Fees do not include sales, use, consumption or excise taxes of any taxing authority. The amount of such taxes, if any, will be added to the Service Fees and Support Fees in effect at the time of delivery and shall be
reflected in the invoices submitted to Zogenix pursuant to this Agreement. 
  

	4.7	Tiered Pricing. 

The Service Fee for the Product will vary depending on the quantity of Product ordered by Zogenix for delivery in a Year, as set out in
Schedule A. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 15 - - 

 ARTICLE 5 

ORDERS, DELIVERY, INVOICING, PAYMENT, MINIMUM VOLUMES, PRODUCT DEFICIENCIES 

 

	5.1	Market Outlook. 

Zogenix acknowledges that for optimal production planning, Patheon requires an understanding of Zogenix’ strategic vision for the
Products in the market and agrees, to the extent that such information (including, if any, Zogenix’ five-year market outlook studies) exists, to share such information with Patheon. 

 

	5.2	Orders and Forecasts. 

Zogenix shall provide Patheon with the following:- 
  

	 	(a)	A written non-binding [***] ([***]) [***] forecast, broken down by month for [***] and [***], of the volume for each Product that Zogenix then anticipates will be
required to be produced and delivered to Zogenix during that [***] ([***]) [***] period. The format of the non-binding [***] ([***]) [***] forecast will be as per the forecast model in Schedule E. Such non-binding forecast will be updated by Zogenix
[***] on a rolling basis. 

  

	 	(b)	Prior to tiered pricing being agreed, Zogenix shall, on or before the fifteenth (15th) day of each calendar month, provide Firm Orders to Patheon for the Products
to be produced and delivered to Zogenix for a period of not less than [***] ([***]) [***] from the first day of the calendar month immediately following the month that the Firm Order is submitted. Such Firm Orders submitted to Patheon shall specify
the Zogenix purchase order number, order quantities by Product type, delivery date and any other elements necessary to ensure the timely production and delivery of the Products. The quantities of Products ordered via Firm Orders shall be binding on
Zogenix and shall not be subject to reduction. Zogenix may request the cancellation of a Firm Order, but the acceptance of such cancellation shall be at the sole discretion of Patheon. 

 

	 	(c)	When tiered pricing has been agreed between the Parties, Zogenix shall, on or before the fifteenth (15th) day of each calendar month, provide firm written orders
(“Firm Orders”) to Patheon for the Products to be produced and delivered to Zogenix for a period of not less than [***] ([***]) [***] from the first day of the calendar month immediately following the month that the Firm Order is
submitted. Such Firm Orders submitted to Patheon shall specify the Zogenix purchase order number, order quantities by Product type, delivery date and any other elements necessary to ensure the timely production and delivery of the Products. The
quantities of Products ordered via Firm Orders shall be binding on Zogenix and shall not be subject to reduction. Zogenix may request the cancellation of a Firm Order, but the acceptance of such cancellation shall be at the sole discretion of
Patheon. For the avoidance of doubt, in the event that Firm Orders are cancelled by Zogenix and such cancellation is accepted by Patheon, then Patheon shall be entitled to charge Zogenix an amount equivalent to the unabsorbed fixed costs associated
with the reduction in expected Firm Orders provided that Patheon uses reasonable commercial efforts to mitigate such costs. For the purposes of this paragraph 5.2(b), it will be considered that Patheon’s fixed costs are equal to [***] of the
Service Fee that would have been payable had the cancelled Firm order been fulfilled. 

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 16 - - 

	 	(d)	In the event Zogenix requires Manufacturing and Support Services for which a Support Fee is due as contemplated in Section 2.1 above, then Patheon shall provide
Zogenix with a quotation which shall be agreed prior to such Manufacturing and Support Services being undertaken by Patheon and Zogenix shall provide Patheon with a purchase order for the same. 

 

	5.3	Reliance by Patheon. 

  

	 	(a)	Materials. For Materials where Patheon is responsible for purchase order placement, as set out in Schedule C, Zogenix understands and acknowledges that Patheon
will rely on the Firm Orders submitted pursuant to Section 5.2(b) in ordering the Materials required to meet such Firm Orders. Patheon understands that Zogenix may request an increase to a Firm Order, pursuant to section 5.2(c), and as such
agrees to maintain inventory sufficient to meet such potential changes. In addition, Zogenix understands that to ensure an orderly supply of Materials, to achieve economies of scale in the costs, or due to minimum and incremental order quantities
imposed by suppliers, Zogenix may agree for Patheon to purchase Materials in sufficient volumes to meet the production demand for Products in excess of the requirements to fulfil Firm Orders. Accordingly, Zogenix may authorise Patheon from time to
time to purchase Materials to satisfy such requirements. If Materials ordered by Patheon pursuant to Firm Orders or this Section 5.3 are not included in finished Products purchased by Zogenix within [***] after the forecasted month in respect
of which such purchases have been made (or such longer period as the parties may agree), Zogenix shall pay to Patheon its costs thereof and, in the event such will receive credit for any costs of such Materials previously paid to Patheon by Zogenix.

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 17 - - 

	 	(b)	Staffing Levels. 

  

	 	(i)	Where the fee for rental of manufacturing space applies: When the forecast demand for the Product, as set out in Section 5.2(a), reaches a level where both Parties
agree it is necessary for Patheon to recruit and train additional staff to move from Shift Pattern B to Shift Pattern C or from Shift Pattern C to Shift Pattern D in order to increase manufacturing Capacity for the Product, then [***].

  

	 	(ii)	Where tiered pricing applies: When the forecast demand for the Product, as set out in paragraph 5.2(a), reaches a level where both Parties agree it is necessary for
Patheon to recruit and train additional staff to move from Shift Pattern A to Shift Pattern B, from Shift Pattern B to Shift Pattern C or from Shift Pattern C to Shift Pattern D in order to increase manufacturing Capacity for the Product, then
[***]. 

  

	 	(iii)	Where Capacity is lower than expected: Where the Capacity is lower than anticipated (as per the Pricing Assumptions) [***]. 

 

	5.4	Order Size. 

Zogenix shall place Firm Orders for the Products in whole multiples of the Standard Batch Size. Zogenix acknowledges that to achieve the
levels of Capacity set out in Schedule A, it will be necessary to manufacture Batches of Product in campaigns and wherever possible, Zogenix will place Firm Orders with delivery dates that enable Patheon to manufacture Product in accordance with the
Minimum Campaign Size set out in Schedule A. Patheon, may be required to accept orders for Products below the Minimum Campaign Size. 
  

	5.5	Rental of Manufacturing Space. 

Zogenix acknowledges that after establishing the infrastructure necessary to provide Manufacturing and Support Services for the Product,
Patheon will incur significant fixed costs. Zogenix also acknowledges that there are opportunity costs for Patheon in dedicating a portion of its Facility exclusively to the manufacture of the Product. Therefore, the Parties hereby agree that, until
such time as the tiered pricing referred to in Section 4.1 above has been agreed between the Parties, Zogenix shall pay to Patheon a rental cost for the area of the Facility required for Manufacturing of [***] per calendar month, payable as set
out in Section 5.9, in consideration of the undertakings and in accordance with the specific terms set out in Schedule A attached hereto. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 18 - - 

	5.6	Delivery. 

  

	 	(a)	INCOTERMS. Delivery of Products or Materials shall be made EXW the Facility unless otherwise mutually agreed. Such title as Patheon has in Products or Materials
and risk of loss or of damage to Products or Materials shall remain with Patheon until Products or Materials are loaded onto the carrier’s vehicle by Patheon for shipment at the Facility at which time title and risk of loss or damage shall
transfer to Zogenix. Patheon shall, in accordance with Zogenix’ instructions and as agent for Zogenix, use / hire the Zogenix-selected freight carrier to ship Products or Materials. 

 

	 	(b)	Volume Variance. Patheon shall make commercially reasonable efforts to ensure that the quantity of Products delivered by Patheon against a Firm Order is [***] of
the quantity indicated on the Firm Order. Patheon will notify Zogenix, in writing or by e-mail, of potential variances that exceed [***]. The Parties will work together to determine how to handle any variance outside of the [***].

 In addition, Patheon shall use reasonable commercial efforts to provide that, at the date of final release by
Patheon, Product supplied to Zogenix shall have a minimum residual shelf life of not less than [***] less than the shelf life of the Product. 
  

	 	(c)	Timing. Patheon will use commercially reasonable efforts and industry standards to provide the facilities, staff and expertise necessary to manufacture
and supply Products as set forth in a Firm Order and in accordance with the terms of this Agreement. Patheon shall use reasonable commercial efforts to ship all Product by the date and in the quantities specified in the applicable Firm Order.
Patheon will notify Zogenix, in writing or by e-mail, of potential delivery delays as soon as is reasonably possible. 

  

	5.7	Invoices and Payment for Service Fees. 

Patheon shall ensure that each invoice is complete, accurate and conforms to the requirements of this Agreement (including carrying out
detailed checks of each invoice before sending the invoice to Zogenix and any checks required by regulatory or government authorities). Patheon will maintain complete and accurate records of, and supporting documentation for, the amounts invoiced to
and payments made by Zogenix hereunder in accordance with generally accepted accounting principles applied on a consistent basis. At Zogenix’ request Patheon will provide Zogenix such other documentation and information with respect to an
invoice as is reasonably requested by Zogenix to verify the accuracy of the invoice and its compliance with this Agreement. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 19 - - 

 Patheon shall invoice Zogenix the Service Fee for the Product upon the satisfactory completion of Batch
review by Patheon’s quality assurance department. Each such invoice shall, to the extent applicable, identify Zogenix purchase order number, Product numbers, names and quantities, the Service Fee per Finished Pack and the total amount to be
remitted by the Zogenix. Invoices submitted to Zogenix shall be addressed “Attention: Accounts Payable” and sent by e-mail to [***] and/or by post or courier to P.O. Box 910687, San Diego, CA 92191, USA. Payment of all such invoices shall
be made by Zogenix within [***] calendar days from the date of invoice. 
  

	5.8	Invoices and Payment for Support Fees. 

Unless otherwise specified in Schedule B, Patheon shall invoice Support Fees to Zogenix upon completion of the activity that such Support
Fees relate to. Each such invoice shall, to the extent applicable, identify Zogenix purchase order number, a description of the activity for which the Support Fee is payable, and the total amount to be remitted by the Zogenix. Invoices submitted to
Zogenix shall be addressed “Attention: Accounts Payable” and sent by e-mail to [***] and/or by post or courier to P.O. Box 910687, San Diego, CA 92191, USA. Payment of all such invoices shall be made by Zogenix within [***] calendar days
from the date of invoice. 
  

	5.9	Invoices and Payment for Rental of Manufacturing Space. 

For each month that the rental fee is payable by Zogenix pursuant to Section 5.5, Patheon shall invoice Zogenix in advance for the
upcoming month and each such invoice shall be payable within [***] days of receipt by Zogenix. Each such invoice shall, to the extent applicable, identify Zogenix purchase order number, state the month that the rental fee covers and the total amount
to be remitted by the Zogenix. Invoices submitted to Zogenix shall be addressed “Attention: Accounts Payable” and sent by e-mail to [***] and by post or courier to P.O. Box 910687, San Diego, CA 92191, USA. Payment of all such invoices
shall be made by Zogenix by the end of the month named in the invoice. 
  

	5.10	Product Deficiencies. 

(a) Inspection. Zogenix shall inspect the Products manufactured by Patheon upon receipt thereof and, within [***] calendar days,
shall give Patheon written notice (a “Deficiency Notice”) of all claims for Products that have not been manufactured according to the Manufacturing Requirements. Should Zogenix fail to provide Patheon with written notice of its
acceptance or rejection within [***] calendar days of receipt of a delivery of Products, then the delivery shall be deemed to have been accepted by Zogenix on the [***] day after delivery. Except as set out in Section 6.2 or for other
deficiencies which could not have been reasonably discovered by means available to Zogenix at the time of acceptance, Patheon shall have no liability for any Product that does not meet the Manufacturing Requirements if Patheon has not received
notice within such [***] calendar day period. 
  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 20 - - 

 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon shall
have [***] business days to advise Zogenix by notice in writing that it disagrees with the contents of such Deficiency Notice. If Zogenix and Patheon fail to agree within [***] business days after Patheon’s notice to Zogenix as to whether any
Products identified in the Deficiency Notice deviate from the Manufacturing Requirements, then the parties shall mutually select an independent third party to evaluate if the Products deviate from the Manufacturing Requirements. Such evaluation
shall be binding on the parties, and if such evaluation certifies that any Products deviate from the Manufacturing Requirements due to Patheon’s acts or omissions constituting a material breach of this Agreement, Zogenix may reject those
Products in the manner contemplated by Section 5.10(c) and Patheon shall be responsible for the payment for the work performed by the independent third party. In addition, at Zogenix’ request, Patheon shall manufacture a replacement batch
of Product at no additional cost to Zogenix and will be liable to Zogenix in amounts not to exceed the limits in Section 9.2(a). If such evaluation does not so certify in respect of any such Products, then Zogenix shall be deemed to have
accepted delivery of such Products on the fortieth day after delivery and Zogenix shall be responsible for payment for the services provided by the independent third party. For any Product rejected by Zogenix, whether the rejection is accepted by
Patheon or is found not to conform by the independent third party due to Patheon’s acts or omissions constituting a material breach of this Agreement, Patheon shall be responsible for all reasonable direct costs relating to return or
destruction of the rejected Product subject to the limitations set out herein. 
 (c) Product rejection during
manufacturing. In the event that deficiencies are identified during the manufacturing process and prior to approval, the Parties agree that: (i) where the deficiency is due to Patheon’s breach of its obligations hereunder then Patheon
shall reimburse Zogenix for any Materials lost subject to the limitations set out in this Agreement; or (ii) where such deficiency is not due to Patheon’s breach of any of its obligations hereunder then Zogenix shall pay Patheon the
applicable Service Fee less any unused Materials. For the avoidance of doubt, no Service Fee will be chargeable if the rejection occurs at a point where Patheon can recommence the manufacture of the batch of Product without any appreciable loss of
Capacity. 
 (d) Product rejection after receipt by Zogenix. Subject to the provisions of Sections 5.10(a) and 9.2(b),
Zogenix has the right to reject and return, at the expense of Patheon, any portion of any shipment of Products that deviates from the Manufacturing Requirements, without invalidating any remainder of such shipment, to the extent that such deviation
arises from Patheon’s negligent or intentional failure to provide the Manufacturing and Support Services in accordance with the Manufacturing Requirements. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 21 - - 

 ARTICLE 6 

CO-OPERATION 
  

	6.1	Joint Steering Committee. 

The Parties shall establish a steering committee, with an equal number of representatives from each of Patheon and Zogenix (the
“Steering Committee”). Both Parties will ensure that their representatives attend regular meetings of the committee and report matters relevant to the performance of this Agreement. The meetings will be chaired by a representative of the
Parties; until the end of the first complete calendar year the chairperson will be nominated by Zogenix, the chairperson for the following calendar year will be nominated by Patheon and the chair will continue to alternate in this way on a
calendar-annual basis. Minutes of the committee’s meetings, to be signed by both Parties, will be circulated to both Parties. 
 The
steering committee will perform the following functions:- 
  

	 	(a)	considering revisions to the Specification and the impact of those revisions upon yields, Capacity, costs and other terms of this Agreement; 

 

	 	(b)	reviewing service levels and the performance of both parties; 

  

	 	(c)	arranging once every three (3) years, a detailed risk analysis of the operation required by this Agreement, agreeing actions to be taken as a result of that
analysis and monitoring the implementation of those actions and reviewing the terms of this Agreement; 

  

	 	(d)	Capacity and contingency planning, investing in increasing Capacity and revisions to the Capacity; 

 

	 	(e)	reviewing the Schedules of this Agreement where relevant; 

  

	 	(f)	such other major functions as the parties jointly agree to assign to it; and 

 

	 	(g)	Review the recommendations of the project co-ordinator (who will be a Patheon employee and be responsible for the day-to-day management of the Agreement and the
co-ordination of any issues arising between the Parties). 

 The Steering Committee may issue recommendations (especially in
technical and pharmaceutical matters) to the parties but cannot bind either party to a legal commitment. However, each Party will reasonably co-operate with the other in implementing the findings of the Steering Committee, to the extent that such
implementation is necessary to give effect to this Agreement and does not unfairly and materially prejudice the interests of that Party. The relevant decisions are to be taken by the Party concerned and shall only be deemed to bind that Party if
confirmed in a written note signed by that Party. 
  

 - - 22 - - 

	6.2	Product Recalls. 

In the event Zogenix believes it may be necessary to conduct a recall, field correction, market withdrawal, stock recovery, or other
similar action with respect to Product (a “Recall”), Zogenix shall make all decisions as to such Recall and Patheon shall cooperate with Zogenix in any Recall. 

To the extent that a Product recall results from, or arises out of, a failure by Patheon to provide the Manufacturing and Support
Services in accordance with the Manufacturing Requirements, such recall shall be made, subject to the limitations as set forth in Section 9.3, at Patheon’s sole cost and expense, and Patheon shall use commercially reasonable efforts to
replace the recalled Products with new Products within [***] days from the date that Zogenix definitively notifies Patheon about the recalled Products, contingent upon the receipt or availability of Materials. In the event that Patheon is unable to
replace the recalled Products within this [***] period (except where such inability results from a failure to receive the required Materials), then Zogenix may request Patheon to reimburse Zogenix for the price that Zogenix paid to Patheon for
manufacturing the affected Products. In all other circumstances, recalls or other corrective actions shall be made at Zogenix’s cost and expense. 
  

	6.3	Governmental Agencies. 

Each party may communicate with any governmental agency, including but not limited to governmental agencies responsible for granting MA
for the Products, regarding such Products if in the opinion of that party’s counsel, such communication is necessary to comply with the terms of this Agreement or the requirements of any law, governmental order or regulation; provided, however,
that unless in the reasonable opinion of its counsel there is a legal prohibition against doing so, such party shall permit the other party to accompany and take part in any communications with the agency, and to receive copies of all such
communications from the agency, subject to redaction of any trade secrets not disclosable. Patheon shall inform Zogenix of any inspection of its facility by the FDA. 
  

	6.4	Records and Accounting by Patheon. 

Patheon shall keep financial records as are necessary to comply with regulatory requirements applicable to Patheon. Copies of such records
shall be retained for a period of time as required by law. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 23 - - 

	6.5	Access, Person in Plant. 

(a) Access. Patheon shall provide Zogenix with reasonable access at mutually agreeable times to areas of the Facility involved in
the manufacture, storage or control of the Product or Materials, subject to Sections 2.1(g) and (n). 
 (b) Person in
Plant. In addition to the access provided for in Section 6.1(a), Patheon shall permit one Zogenix employee to be permanently located within the Facility during the term of the Agreement ( the “PIP”). Patheon will provide the PIP
with reasonable office space within the Facility and the PIP shall have access to such office space during regular working hours throughout the term of the Agreement. The PIP shall comply with any and all confidentiality, security, safety, quality
or similar guidelines that apply to persons present in the Facility and that are communicated by Patheon. The cost of this provision is included in the rental fee. 
  

	6.6	Subordination and Waiver Agreement. 

Patheon will agree to execute a Subordination and Waiver Agreement with Zogenix and GE Capital Corporation (“GE”) (and
any other lender to Zogenix) in a form reasonably agreeable to Patheon with respect to specified Zogenix assets used in the performance of services under this Agreement. 

 

	6.7	Relationship Manager. 

Each Party shall forthwith upon execution of this Agreement appoint one of its employees to be a relationship manager responsible for
liaison between the parties. The relationship managers shall meet whenever necessary and appropriate to review the current status of the business relationship and manage any issues that have arisen, including costs. 

 

 - - 24 - - 

 ARTICLE 7 

TERM AND TERMINATION 
  

	7.1	Term. 

 This Agreement shall become
effective as of the Effective Date and shall continue for a period of five (5) years from such date (the “Initial Term”), unless terminated earlier by one of the Parties as provided herein. Either Party may terminate this
Agreement by serving no less than [***] months written notice to the other. The Parties may mutually agree in writing to renew the Agreement for additional terms prior to the expiration of the Initial Term or the then current term. 

 

	7.2	Termination for Cause. 

(a) Either party at its sole option may terminate this Agreement upon written notice in circumstances where the other party has failed to
remedy a material breach of any of its representations, warranties or other obligations under this Agreement within [***] calendar days following receipt of a written notice (the “Remediation Period”) of said breach that expressly
states that it is a notice under this Section 7.2(a) (a “Breach Notice”). The aggrieved party’s right to terminate this Agreement pursuant to this Section 7.2(a) may only be exercised for a period of [***] calendar
days following the expiry of the Remediation Period (in circumstances where the breach has not been remedied) and if the termination right is not exercised during this period then the aggrieved party shall be deemed to have waived the breach of the
representation, warranty or obligation described in the Breach Notice. 
 (b) Either party at its sole option may immediately
terminate this Agreement upon written notice, but without prior advance notice, to the other party in the event that: 
  

	 	(i)	the other party is declared insolvent or bankrupt by a court of competent jurisdiction; 

 

	 	(ii)	a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such other party; or 

 

	 	(iii)	this Agreement is assigned by such other party for the benefit of creditors. 

(c) Patheon may terminate this Agreement on [***] months’ prior written notice if the Zogenix assigns pursuant to Section 12.5
any of its rights under this Agreement to an assignee that, in the opinion of Patheon acting reasonably, is: 
  

	 	(i)	[***]; or 

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 25 - - 

	 	(ii)	[***]; or 

  

	 	(iii)	[***]. 

  

	7.3	Obligations on Termination. 

If this Agreement expires or is terminated in whole or in part as per 7.2 or as defined in this Agreement, then (in addition to any other
remedies Patheon may have in the event of default by Zogenix):- 
  

	 	(a)	Zogenix shall take delivery of and pay for all undelivered Products that are manufactured and/or packaged pursuant to a Firm Order, at the price in effect at the time
the Firm Order was placed; 

  

	 	(b)	Zogenix shall purchase, at Patheon’s cost, the Inventory applicable to the Products which was purchased, produced or maintained by Patheon in contemplation of
filling Firm Orders or in accordance with Section 5.3 prior to notice of termination being given; 

  

	 	(c)	Zogenix shall satisfy the purchase price payable pursuant to Patheon’s orders with suppliers of Materials, provided such orders were made by Patheon in reliance on
Firm Orders or in accordance with Section 5.3; and 

  

	 	(d)	Zogenix shall pay to Patheon removal and Make Good Costs associated with the removal of any of its Equipment from the Facility. For the avoidance of doubt, the Make
Good Costs shall be limited to a maximum financial contribution of [***] all as evidenced by appropriate documentation provided by Patheon; and 

  

	 	(e)	Patheon shall return to Zogenix or dispose of all unused Materials (with shipping, disposal and related expenses, if any, to be borne by Zogenix); and

  

	 	(f)	Except where termination of the Agreement is a result of an unremediated breach by Zogenix, Patheon will provide exit services necessary to support the manufacture of
Product up until such time as commercial production capability has been established in an alternative location. Zogenix will pay Patheon for the services rendered, including but not limited to production and technology transfer support, charged at
rates determined in good faith between the parties; and 

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 26 - - 

	 	(g)	Where termination of the Agreement is a result of an unremediated breach by Zogenix, Patheon shall cease all Manufacturing and Support Services, except those quality
and other activities that must by applicable law be continued; and 

  

	 	(h)	[***]. 

  

	 	(i)	In addition, but only in the event of either: [***]. 

Any termination or expiration of this Agreement shall not affect any outstanding obligations or payments due hereunder prior to such
termination or expiration, nor shall it prejudice any other remedies that the parties may have under this Agreement. For greater certainty, termination of this Agreement for any reason shall not affect the obligations and responsibilities of the
parties pursuant to Article 9, all of which survive any termination. In addition thereto and for the avoidance of doubt, in the event that Zogenix reasonably believes that Patheon does not intend to fulfil its obligations hereunder and intends to
terminate the Agreement contrary to the provisions herein for no legal or equitable reason then, in the case of such anticipatory breach, the parties agree that, in addition to the other remedies available herein, Zogenix reserves the right to
equitable relief and to apply to the applicable court for an order for such specific performance or such other injunctive relief as may be available in equity in order to prevent irreparable harm being inflicted upon Zogenix and to ensure
Patheon’s continued performance hereunder and, furthermore, Patheon shall not unreasonably challenge such application or order obtained thereunder. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 27 - - 

 ARTICLE 8 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	8.1	Authority. 

 Each
party covenants, represents and warrants that it has the full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder. 

 

	8.2	Covenants, Representations and Warranties. 

Zogenix covenants, represents and warrants that: 

(a) the Specifications for each of the Product(s) are its property and that Zogenix may lawfully disclose the Specifications to Patheon;

 (b) any Intellectual Property utilised by Patheon in connection with the provision of the Manufacturing and Support Services
according to the Specifications 
  

	(i)	is Zogenix’ unencumbered property, 

  

	(ii)	may be lawfully used as directed by Zogenix, and 

  

	(iii)	such use does not infringe and will not infringe any Third Party Rights; 

(c) the provision of the Manufacturing and Support Services by Patheon in respect of any Product pursuant to this Agreement or use or
other disposition of any Product by Patheon as may be required to perform its obligations under this Agreement does not and will not infringe any Third Party Rights; 

(d) there are no actions or other legal proceedings, the subject of which is the infringement of Third Party Rights related to any of the
Specifications, or any of the Materials, or the sale, use or other disposition of any Product made in accordance with the Specifications; 

(e) the Specifications for all Products conforms to all applicable cGMPs, laws and regulations; and 

(f) the Products, if labelled and manufactured in accordance with the Specifications and in compliance with applicable cGMPs: 

 

	 	(i)	may be lawfully sold and distributed in the Territory, 

  

	 	(ii)	will be fit for the purpose intended, and 

  

 - - 28 - - 

	 	(iii)	will be safe for human consumption. 

  

	8.3	Permits. 

 (a)
Zogenix shall be solely responsible for obtaining or maintaining, on a timely basis, any permits or other regulatory approvals in respect of the Products or the Specifications, including, without limitation, all marketing and post-marketing
approvals. 
 (b) Patheon shall maintain all licenses, permits, and approvals required by all applicable governmental entities
and under all applicable Laws for its manufacturing facilities and the performance of its obligations hereunder. 
  

	8.4	Compliance with Laws. 

Each party, in connection with its performance under this Agreement, shall comply with all applicable laws, rules, regulations and orders.

  

	8.5	Patheon Representations, Covenants and Limited Warranty. 

Patheon covenants, represents and warrants that: 
  

	 	(a)	all Products manufactured, packaged and tested by it hereinafter shall comply with cGMPs, Manufacturing Requirements, the MA and Specifications; and

  

	 	(b)	all Products delivered by it to Zogenix shall not be “adulterated” as that term is defined in the FDC Act and other applicable laws; and

  

	 	(c)	Patheon shall be responsible for obtaining and shall obtain all necessary environmental or other licenses, certificates, approvals or permits required under applicable
law and any private permissions, whether original documents or modifications to existing documents, which are necessary to manufacture the Product at the Facility and shall provide copies thereof to Zogenix upon request by Zogenix. Patheon shall
provide Zogenix with immediate verbal notice, confirmed in writing within twenty-four (24) hours, in the event of revocation or modifications of any license, certificate, approval or permit, or in regard to any other event or regulatory action
or involvement, such as an order or notice, which in any way impacts upon Patheon’s ability to manufacture and deliver the Product or use of the Facility. 

 

	 	(d)	as of the date hereof: (i) Patheon is, and during the term of this Agreement Patheon shall continue to be, in full compliance with applicable law; and
(ii) Patheon holds all licenses, permits, registrations and similar governmental authorizations necessary or required for Patheon to conduct its operations and business and is in compliance with all such licenses, permits, registrations and
authorizations; and 

  

 - - 29 - - 

	 	(e)	No receiver, administrative receiver or administrator has been appointed nor any notice given, petition presented or order made for the appointment of any such person
over the whole or any part of the assets or undertaking of Patheon; and 

  

	 	(f)	No petition has been presented, no order has been made and no resolution has been passed for the winding up of Patheon or for the appointment of a liquidator or
provisional liquidator of Patheon; and 

  

	 	(g)	No voluntary arrangement has been proposed or is in force under the Insolvency Act 1986 Section 1 in respect of Patheon; and 

 

	 	(h)	No unsatisfied judgment is outstanding against Patheon and no demand has been served on the Company under the Insolvency Act 1986 Section 123(1)(a); and

  

	 	(i)	There are not pending or in existence any investigations or inquiries by or on behalf of any governmental or other body in respect of the affairs of Patheon; and

  

	 	(j)	None of the activities or contracts or rights of Patheon is ultra vires, unauthorised, invalid or unenforceable or in breach of any contract or covenant; and

  

	 	(k)	Patheon is empowered and duly qualified to carry on business in all jurisdictions in which it now carries on business and is duly authorised to enter into this
Agreement; and 

  

	 	(l)	it is the exclusive legal and beneficial owner or legitimate licensee of all rights, title and interest in any intellectual property it may use in order to fulfil its
obligations hereunder and there are no liens, encumbrances or other charges over any of them; and 

  

	 	(m)	in the event that Patheon wishes to enter into any competitive arrangements during the Term hereof Patheon undertakes that, prior to the commencement of such
activities, the relevant third party shall perform a full and reasonable investigation into any potential conflicts relating to the prior art of Zogenix and provide Patheon with evidence of the same. In the event that there is evidence of a conflict
then Patheon agrees not to enter into a manufacturing agreement with such third party. 

 PATHEON MAKES NO OTHER WARRANTY OF
ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. PATHEON MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF MERCHANTABILITY. 

 

 - - 30 - - 

 ARTICLE 9 

REMEDIES AND INDEMNITIES 
  

	9.1	Consequential Damages. 

Under no circumstances whatsoever shall either party be liable to the other in contract, tort, negligence, breach of statutory duty or
otherwise for any (direct or indirect) loss of profits, of production, of anticipated savings, of business or goodwill or for any liability, damage, costs or expense of any kind incurred by the other party of an indirect or consequential nature.

  

	9.2	Limitation of Liability. 

(a) Materials. Patheon shall not be responsible for any loss or damage to the Materials paid for by Zogenix, as set out in Schedule
C, except for any loss or damage resulting from Patheon’s negligence in handling or storage of the Materials or any act or omission by Patheon in the manufacture of the Product not in compliance with cGMPs or the Manufacturing Requirements.
Patheon shall reimburse Zogenix for the cost of such Materials used in any Batch not found to meet Specifications after manufacture pursuant to resolution under Section 5.9(b), or where it agrees that its acts or omission in the manufacture
caused the failure of the Product not to conform, or any lost or damaged Materials resulting from Patheon’s negligence in handling or storage of the Materials, up to an amount not to exceed [***]. 

However, notwithstanding the aforementioned, if Patheon loses or damages Zogenix Materials whilst such Materials are being stored (either in their raw
form or in finished Product form) then, provided such loss is recoverable under Patheon’s insurance policy and not subject to any “all risks” exclusions, and, more specifically, such Materials were not lost or damaged due to an error
or errors in processing or manufacturing of Zogenix’ Product or Materials while being worked upon (such losses being specifically limited in the above paragraph and not applicable, howsoever caused, herein unless loss or damage from a peril
insured herein ensues and then this policy shall cover for such ensuing loss or damage) then Patheon shall reimburse Zogenix for the loss of such Materials up to the amount recoverable from its insurer provided, however, that Zogenix agrees and
understands that Patheon shall only insure Zogenix Materials up to the values recommended and provided to Patheon by Zogenix. For the avoidance of doubt, in the event any such losses are unrecoverable due to the under-estimation of such values, then
Patheon shall not be liable for such unrecoverable losses. Any payment made hereunder shall further be subject to any deductible amounts applied by the insurer. For the avoidance of doubt the coverage rate for property is [***]. For the first Year
of the Agreement Zogenix have stated that, at any given time, there will be no more that [***] of Product and Materials stored at Patheon’s Facility (the insurance premium, payable by Zogenix, is [***]. This limit shall be reviewed and agreed
each year of the Agreement by the Parties and confirmed in writing separately. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 31 - - 

 (b) Products. Except in circumstances where Patheon has failed to provide the
Manufacturing and Support Services in accordance with the Manufacturing Requirements, or except as provided in Sections 9.3 or 9.2, Patheon shall not be liable nor have any responsibility for any deficiencies in, or other liabilities associated
with, any Product manufactured by it, including, without limitation, any deficiencies with respect to the Specifications, the safety, efficacy or marketability of the Products or any distribution thereof. 

(c) Nothing in this Agreement is intended to limit either party’s liability for claims for losses relating to death or bodily injury
or resulting from the fraudulent misrepresentation of a party. 
  

	9.3	Patheon. 

 Subject
to Sections 9.1 and 9.2, Patheon agrees to defend, indemnify and hold Zogenix, its officers, employees and agents harmless against any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties
(“Claim(s)”) resulting from, or relating to any Claim for damages or losses or property damage to the extent that such loss, injury or damage is the result of a failure by Patheon to provide the Manufacturing and Support Services in
accordance with the Manufacturing Requirements or in breach of the warranties made herein. Such indemnity shall be limited to an amount not to exceed [***]. For avoidance of doubt, the limits on Patheon’s liability shall not be cumulative over
the Term of the Agreement. 
 In the event of a Claim, Zogenix shall: 

 

	 	(a)	promptly notify Patheon of any such claim; 

  

	 	(b)	use commercially reasonable efforts to mitigate the effects of such claim; 

 

	 	(c)	reasonably cooperate with Patheon in the defence of such claim; 

  

	 	(d)	permit Patheon to control the defence and settlement of such claim, all at Patheon’s cost and expense. 

 

	9.4	Zogenix. 

 Subject
to Sections 9.1 and 9.2, Zogenix agrees to defend, indemnify and hold Patheon, its officers, employees and agents harmless against any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties
resulting from, or relating to any claim of infringement or alleged infringement of any Third Party Rights in respect of the Products, and any claim of bodily injury or property damage to the extent that such injury or damage is the result of a
breach of this Agreement by Zogenix, including, without limitation, any representation or warranty contained herein, except to the extent that any such losses, damages, costs, claims, demands, judgments and liability are due to the negligence or
wrongful act(s) of Patheon, its officers, employees or agents. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 32 - - 

 In the event of a claim, Patheon shall: 

 

	 	(a)	promptly notify Zogenix of any such claims; 

  

	 	(b)	use commercially reasonable efforts to mitigate the effects of such claim; 

 

	 	(c)	reasonably cooperate with Zogenix in the defence of such claim; 

  

	 	(d)	permit Zogenix to control the defence and settlement of such claim, all at Zogenix’ cost and expense. 

 

 - - 33 - - 

 ARTICLE 10 

CONFIDENTIALITY 
  

	10.1	Confidentiality. 

The Parties agree that they are governed by the provisions of the Confidentiality Agreement, which agreement remains in effect in
accordance with its terms. 
  

	10.2	Confidential Information 

Except as expressly provided, the Parties agree that, for the Term and [***] years thereafter, the receiving Party shall keep completely
confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing Party hereto pursuant to this Agreement.

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 34 - - 

 ARTICLE 11 

DISPUTE RESOLUTION 
  

	11.1	Commercial Disputes. 

In the event of any dispute arising out of or in connection with this Agreement (other than a dispute determined in accordance with
Section 5.9(b) or a Technical Dispute), the parties shall first try to solve it amicably. In this regard, any party may send a notice of dispute to the other, and each party shall appoint, within ten (10) Business Days from receipt of such
notice of dispute, a single representative having full power and authority to solve the dispute. The representatives so designated shall meet as necessary in order to solve such dispute. If these representatives fail to solve the matter within one
month from their appointment, or if a party fails to appoint a representative within the ten (10) Business Days period set forth above, such dispute shall immediately be referred to the Chief Operating Officer or Executive Vice President,
Operations (or such other officer as they may designate) of Patheon and the President and Chief Executive Officer of Zogenix who will meet and discuss as necessary in order to try to solve the dispute amicably. Should the parties fail to reach a
resolution under this Section 11.1, their dispute will be settled in accordance with Section 12.14. 
  

	11.2	Technical Dispute Resolution. 

In the event of a dispute (other than disputes in relation to the matters set out in Sections 5.8(b) and 11.1) between the parties that is
exclusively related to technical aspects of the manufacturing, packaging, labelling, quality control testing, handling, storage or other activities under this Agreement (a “Technical Dispute”), the parties shall follow the process
for conflict resolution set out in the Quality Agreement. In the event that the parties cannot agree whether a dispute is a Technical Dispute, Section 11.1 shall prevail. 

 

 - - 35 - - 

 ARTICLE 12 

MISCELLANEOUS 
  

	12.1	Intellectual Property. 

Zogenix and Patheon hereby acknowledge that neither party has, nor shall it acquire, any interest in any of the other party’s
Intellectual Property or Improvements thereto unless otherwise expressly agreed to in writing. Each party agrees not to use any Intellectual Property of the other party, except as specifically authorised by the other party or as required for the
performance of its obligations under this Agreement. 
 Improvements to any and all aspects of the technology solely applicable
to the manufacturing of the Product shall be wholly owned by Zogenix. Patheon shall own any manufacturing processes of a generic nature that it develops or any Improvements to any pre-owned Patheon intellectual property or know-how. However, in the
event that Zogenix requires the use of any Patheon owned intellectual property, know-how or Improvements in order to manufacture the Product then Patheon shall grant a non-exclusive, royalty-free, worldwide license to Zogenix for use of the same
solely in relation to the manufacturing, sale or distribution of the Product. For the avoidance of doubt nothing contained herein shall operate or is intended to provide one party with any rights over the Intellectual Property rights of the other
party or any Improvements thereto unless explicitly stated herein. 
  

	12.2	Insurance. 

 Each
party shall maintain commercial general liability insurance to include products liability coverage for bodily injury, which insurance shall afford limits of not less than GBP 2,500,000 for each occurrence (and in the aggregate only with respect to
bodily injury liability) with a reputable insurance carrier. Each party will provide the other with a current certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the
expiration date and the limits of liability. The insurance certificate shall further provide that the carrier will endeavour to provide a minimum of thirty (30) days’ written notice to the insured of a cancellation of, or material change
in, the insurance. 
  

	12.3	Independent Contractors. 

The parties are independent contractors and this Agreement shall not be construed to create between Patheon and Zogenix any other
relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners or any similar relationship, the existence of which is expressly denied by the parties hereto. 

 

	12.4	No Waiver. 

 Except
as provided by Section 7.2, either party’s failure to require the other party to comply with any provision of this Agreement shall not be deemed a waiver of such provision or any other provision of this Agreement. 

 

 - - 36 - - 

	12.5	Assignment. 

Patheon may assign this Agreement or any of its rights or obligations hereunder with the prior written consent of Zogenix, such consent to
be given provided that the assignee covenants in writing with Zogenix to be bound by the terms of this Agreement. Subject to Section 7.3(c), Zogenix may assign this Agreement or any of its rights or obligations hereunder without approval from
Patheon; provided, however, that Zogenix shall give prior written notice of any assignment to Patheon and any assignee shall covenant in writing with Patheon to be bound by the terms of this Agreement. Notwithstanding the foregoing provisions of
this Section 12.5, either Party may assign this Agreement to any of its Affiliates or to a successor to or purchaser of all or substantially all of its business, provided that such assignee executes an agreement with the non-assigning party
hereto whereby it agrees to be bound hereunder. 
  

	12.6	Force Majeure. 

Non-performance by either party hereto shall be excused to the extent that performance is rendered impossible by strike, lock out or
labour disturbance, fire, explosion, flood, acts of God, terrorism, war or civil commotion, governmental acts or orders or restrictions, public utilities or common carriers, or any other reason where failure to perform is beyond the reasonable
control of and is not caused by the negligence of the non-performing party. Such non-performing party shall exercise best efforts to eliminate the force majeure event and to resume performance of its affected obligations as soon as practicable. In
the event that, as a result of such force majeure event, a party does not perform all of its obligations hereunder for any period of [***] consecutive days, in addition to any other rights hereunder, the other party may terminate this Agreement on
[***] days prior written notice to the non-performing party. A party claiming a right to excused performance under this Section 12.6 shall immediately notify the other party in writing of the extent of its inability to perform, which
notice shall specify the occurrence beyond its reasonable control that prevents such performance. Neither party shall be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for delayed
payment) which would otherwise be due and payable under this Agreement. 
  

	12.7	Additional Product. 

Additional products may be added to this Agreement and such additional products shall be governed by the general conditions hereof with
any special terms (including, without limitation, price) governed by an addendum hereto. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 37 - - 

	12.8	Notices. 

 All
communications and other notices under this Agreement shall be in writing and shall be considered as duly given if sent by fax and confirmed by registered letter sent within two (2) Business Days following the date of the fax to the Parties at
the following addresses (or at any other address which the parties shall have indicated giving notice thereof in the ways set forth above): 
  

	 	a)	as to Zogenix, to: 

 Zogenix,
Inc. 
 Attention: Chief Financial Officer 

12671 High Bluff Drive, Suite 200 

San Diego 

California, 92130 

U.S.A. 
 Tel.
No.:        +1 858 436 8594 
 Fax
No.:         +1 858 259 1166 
  

	 	b)	as to Patheon, to: 

 Patheon
UK Limited. 
 Attention: Executive Director and General Manager 

Kingfisher Drive 

Covingham 

Swindon 

Wiltshire SN3 5BZ 

England 
 Tel.
No.:        + 44 (0) 1793-524-411 
 Fax
No.:         + 44 (0) 1793-487-053 
 All the communications and other notices under this
Agreement which have been delivered in person or which have been transmitted by fax and confirmed by registered letter sent within 2 (two) working days following the date of the fax, shall be considered as received by the addressee respectively upon
the third Business day subsequent to that of the date of the fax. 
  

	12.9	Severability. 

 If
any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such determination shall not impair or affect the validity, legality or enforceability of the remaining
provisions hereof, and each provision is hereby declared to be separate, severable and distinct. 
  

	12.10	Entire Agreement. 

 Upon the
Effective Date this Agreement, together with the Quality Agreement and the Confidentiality Agreement, constitutes the full, complete, final and integrated agreement between the parties hereto relating to the subject matter hereof and, unless
expressly stated otherwise in this Agreement, supersedes all previous written or oral negotiations, commitments, agreements, transactions or understandings with respect to the subject matter hereof including but not limited to the Binding Letter
Agreement and the Occupancy Agreement. Any modification, amendment or supplement to this Agreement must be in writing and signed by authorised representatives of both parties. The Quality Agreement takes precedence over the Agreement on
quality & regulatory issues, on all other matters the Agreement shall prevail. 
  

 - - 38 - - 

	12.11	No Third Party Benefit or Right. 

For greater certainty, nothing in this Agreement shall confer or be construed as conferring on any third party any benefit or the right to
enforce any express or implied term of this Agreement. Pursuant to section 1(2) of the Contracts (Rights of Third Parties) Act 1999 the parties intend that no term of this Agreement may be enforced by a Third Party. 

 

	12.12	Execution. 

 This
Agreement shall be executed in duplicate signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

	12.13	Governing Law. 

This Agreement shall be construed and enforced in accordance with the laws of England and the parties hereby agree to the exclusive
jurisdiction of the courts of England without giving effect to the conflict of laws principles thereof. The parties further expressly agree that the 1980 United Nations Convention on Contracts for the International Sale of Goods (and any
improvements or additions thereto) shall not apply to this Agreement. 
  

	12.14	Resolution. 

In the event of any dispute, controversy or claim arising out of, relating to or in connection with any provision of this Agreement, the
parties shall first try to settle their differences amicably via the Steering Committee. If the Joint Steering Committee cannot achieve resolution, then the matter will be referred to Patheon and Zogenix Senior Management. If Patheon and Zogenix
Senior Management cannot achieve resolution, either party may seek to have such dispute resolved by a competent court as stated in Section 12.13. 
  

	12.15	Publicity of Agreement. 

Neither party shall use the name of the other party in any publicity, advertising or in any written, verbal or any other form of public
disclosure without the express written consent of the other party, including references to the existence of and the relationship created under this Agreement, except as required by law or regulation. 

 

 - - 39 - - 

 IN WITNESS WHEREOF, the duly authorised representatives of the parties have executed this
Agreement as of the date first written above. 
  

			
	 PATHEON UK LIMITED

		
	By	 	 /s/ Aldo Braca

	
	 Aldo Braca

	 President, Patheon Europe

			
		
	Date	 	
 

			
	
	 ZOGENIX, INC.

		
	By	 	 /s/ Roger Hawley

	
	 Roger Hawley

	 Chief Executive Officer

			
		
	Date	 	Nov. 6, 2008

  

 - - 40 - - 

 SCHEDULE A 

PRODUCTS, SERVICE FEES, PRICING ASSUMPTIONS, RENTAL FEES 

Products 
 The Products covered under
this Agreement are as follows: 
  

							
	 Description
	  	 Finished Pack
	  	 
	1.	  	DoseProTM Sumatriptan 6mg/0.5mL (Trade)	  	6 Units per carton	  	
	2.	  	DoseProTM Sumatriptan 6mg/0.5mL (Sample)	  	4 Units per carton	  	
	3.	  	DoseProTM Sodium Chloride 0.9% Solution	  	6 Units per carton	  	
	4.	  	DoseProTM Unfilled Assembled Devices	  	N/A	  	

 Service Fee 

The Parties agree that, once the Pricing Assumptions below have been reasonably confirmed (or varied by mutual agreement, as the case may be) then a
tiered pricing schedule shall be confirmed and agreed in writing between the parties substantially in the form as set out immediately below. The prices stated below are for initial purposes only and are reduced to reflect the additional revenue
received from the rental fee set out in Section 5.5 of the Agreement and are subject to change accordingly. For the avoidance of doubt, Service Fees applicable to tiered pricing after cessation of the rental fee will be higher than that stated
below. 
 Unit = One DoseProTM device. 

Conversion Fee = The Service Fee less the cost of Materials purchased by Patheon. 

The Service Fee for the first [***] Units ordered for delivery in a Year is as follows (individual Material costs are set out in Table A-2 below but the
costs of certain Materials are to be confirmed and the Parties will update Table A-2 as soon as actual costs are confirmed by the relevant third party supplier):- 
  

									
	 Product
	  	Conversion
Fee per Unit	 	Conversion Fee
per Finished Pack	 	Estimated Cost of
Materials per
Finished Pack	 	Service Fee per
Finished Pack
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	 	[***]	 	[***]	 	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	 	[***]	 	[***]	 	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	 	[***]	 	[***]	 	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	 	[***]	 	[***]	 	[***]

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 41 - - 

 The Service Fee for the [***] to the [***] Unit ordered for delivery in a Year is as follows: 

 

									
	 Product
	  	Conversion Fee
per Unit	 	Conversion Fee
per Finished Pack	 	Estimated Cost of
Materials per
Finished Pack	 	Service Fee per
Finished Pack
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	 	[***]	 	[***]	 	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	 	[***]	 	[***]	 	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	 	[***]	 	[***]	 	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	 	[***]	 	[***]	 	[***]

 Pricing Assumptions

 Patheon has based the Service Fee for the Product on the following assumptions (the “Pricing Assumptions”): 

 

	A.	[***]. 

  

	B.	[***]. 

  

	C.	[***]. 

  

	D.	[***]. 

  

	E.	[***]. 

  

	F.	[***]. 

  

	G.	[***]. 

  

	H.	[***]. 

  

	I.	[***]. 

  

	J.	[***]. 

  

	K.	[***]. 

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 42 - - 

 Standard Batch Size 

The Standard Batch Size for the Product is the expected yield from the current validated Batch size (expressed in Units) after secondary packaging from a
standard Batch of bulk Product, taking into account normal production losses and routine sampling for in process controls, finished product testing and retain samples. For the purposes of calculating theoretical Capacity, a Standard Batch Size for
the Product has been assumed for Table A-1. For the avoidance of doubt, the Standard Batch Size shown in Table A-1 may vary from the current validated Batch size, as process optimisation will be required in order to increase the annual Capacity for
the Product to the levels set out in Table A-1. For the purposes of ordering and forecasting under Section 5.2, the Standard Batch Size shall be the current validated Batch size, as updated and agreed in writing by the Parties from time to
time. 
 Minimum Campaign Size 

The Minimum Campaign Size for the Product is the minimum number of Product Batches that will be run consecutively before critical equipment and area
cleaning activities must be performed. The Minimum Campaign Size for the Product is dependent on the shift pattern being utilised and set out in Table A-1. Process optimisation will be required in order to increase the annual Capacity for the
Product to the levels set out in Table A-1. 
  

 - - 43 - - 

 TABLE A-1 

 

											
	 Shift Pattern
	  	Annual Capacity
(Units)	 	Bulk Batch Size (L)	 	Standard Batch Size
(Units)	 	Minimum Campaign
Size (Batches)	 	Batches per week
	 A
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 B
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 C
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 D
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 Shift Pattern A 

[***] 
 Shift Pattern B 

[***] 
 Shift Pattern C 

[***] 
 Shift Pattern D 

[***] 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 44 - - 

 TABLE A-2 

MATERIALS COST 
 DoseProTM
Sumatriptan 6mg/0.5mL (Trade) x 6’s 
 DoseProTM Sodium Chloride 0.9% Solution x 6’s 

 

															
	 Code
	  	 Description
	  	Quantity	  	UOM	  	Unit Cost	  	UOM	  	Bach Cost
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  		  		  		  	Materials Cost per Batch	  	[***]
	 Packed Yield
	  	[***]	  		  		  	Materials Cost per Pack	  	[***]

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 45 - - 

 MATERIALS COST 

DoseProTM Sumatriptan 6mg/0.5mL (Sample) x 4’s 
  

															
	 Code
	  	 Description
	  	Quantity	  	UOM	  	Unit Cost	  	UOM	  	Bach Cost
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		  		  		  		  	Materials Cost per Batch	  	[***]
	 Packed Yield
	  	[***]	  		  		  	Materials Cost per Pack	  	[***]

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 46 - - 

 SCHEDULE B 

SUPPORT FEES 
 The
charges and fees set out below shall apply as and when indicated for the related services. For the avoidance of doubt Zogenix shall be informed of and agree in writing to any such charges being made and issue a purchase order prior to them being
incurred by Patheon. 
 Stability Testing Fees 

Where Patheon is required to perform stability testing over and above the Annual Stability Commitment, Patheon will charge Zogenix [***] per test point
and per storage condition on said Batch. If stability samples are placed on stability storage at the Facility, this fee includes the cost of storing the stability samples. In the event that the stability samples are placed on stability storage at
the facility of a third party, then the costs of such storage shall be invoiced by Patheon to Zogenix at Patheon’s direct cost. 
 For the
avoidance of doubt, a test point shall be considered any stability testing performed at a discrete point in time subsequent to release testing for a Batch, such test points to be defined in the stability protocol provided by Zogenix. A storage
condition shall be considered any unique combination of storage requirements including but not limited to temperature, humidity, orientation of samples and packaging, with such storage conditions to be defined in the stability protocol provided by
Zogenix. 
 Patheon shall calculate the total stability testing fee per Batch of product placed on stability based on the number of test points
specified in the stability protocol provided by Zogenix and invoice Zogenix 50% of said fee once samples are placed in stability storage, with the balance of the stability fee to be invoiced upon completion of testing on the final stability test
point for that Batch. The Client shall pay all such invoices within thirty days of the date thereof. 
 Maintenance of Regulatory Filings

 Patheon will invoice Zogenix for regulatory activities requested by Zogenix for submission or maintenance of regulatory filings for the
Product at the rates set out in the table below. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 47 - - 

					
	REGULATORY SUPPORT ACTIVITIES
	Site Related
			
	 Activity
	  	 Definition
	  	 Fee

	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
		  	[***]	  	
		  	[***]	  	[***]
		  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
		  	[***]	  	[***]
	  
 Product
Related

			
	 Activity
	  	 Definition
	  	 Fee

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	  

Miscellaneous

			
	 Activity
	  	 Definition
	  	 Fee

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

 Batch Record and Specification
Update 
 Pursuant to Section 2.1(j), Patheon shall invoice the Client [***]. 

Product Quality Review 
 Where Patheon is
requested by Zogenix to provide data over and above the PQR Data or where Patheon is requested by Zogenix to perform trending and critical analysis on the PQR Data, Patheon will invoice Zogenix at a rate of [***]. 

 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 48 - - 

 Audit Support 

Patheon’s fee for providing audit support where more than [***] per annum at the Facility is requested by the client, as set out in
Section 2.1(g), [***]. 
 Artwork Generation and Update 

Patheon will invoice Zogenix for artwork generation and update services the fees set out in the table below. 

 

					
	 	  	Generation /Update Fee	 	Fee per Colour
	 Carton
	  	[***]	 	[***]
	 Label
	  	[***]	 	[***]
	 Leaflet
	  	[***]	 	[***]

 For example, the fees for a three-colour carton
would be: 
 [***] 
 If the items
listed below are required for the carton, the following fees will apply: 
 [***] 

Additional Sampling 
 Patheon will
invoice additional samples to Zogenix at the agreed Service Fee for a Product or the direct cost for a Material. Patheon will also charge Zogenix an administration fee of [***]. 

Freight Charges 
 Any freight charges
incurred by Patheon on behalf of Zogenix for the shipment of Product or Materials shall be invoiced by Patheon to Zogenix at [***]. For the avoidance of doubt, freight charges for the delivery of Materials to the Facility are included in the cost of
Materials, which are included in the Service Fee and will not be invoiced separately to Zogenix by Patheon. 
 Additional Testing

 Patheon’s fee to Zogenix for additional testing will be assessed on a case by case basis and will be dependent on the scope of work
required by Zogenix. 
  

 - - 49 - - 

 Process Optimisation and Project Activities 

Patheon’s fees for performing optimisation and project activities will be assessed on a case by case basis depending on the scope of work required
and will be agreed between the Parties prior to such activities being commenced. For the avoidance of doubt, project activities include, by way of illustration and not limitation, initial validation and qualification activities and Product (and
future product) development work but do not include work that can, by agreement between the Parties, be covered by the existing resources allocated to the Manufacturing Services. 

 

 - - 50 - - 

 SCHEDULE C 

MATERIALS 
  

															
	 Materials
	  	Vendor Supply
Agreement	 	MRP	 	Purchase Order
Placement	 	Invoice Receipt	 	Invoice Payment	 	Setting Safety
Stock Levels	 	Physical Stock
Holding
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

					
	Z = The Client	 	P = Patheon	 	N/A = Not Applicable

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 51 - - 

 SCHEDULE D 

EQUIPMENT 

PREAMBLE 
  

	 	1.	All capitalised terms used in this Schedule (“Schedule D”) shall bear the same meaning as in the Agreement unless expressly stipulated otherwise herein.

  

	 	2.	It is understood that Zogenix owns all Equipment listed herein and title, risk and ownership thereof remains either with Zogenix or with GE at all times as per the
terms of the Deed signed between the Parties and GE. 

  

	 	3.	This Schedule D shall come into force when the Agreement is signed by both Parties. 

 

	 	4.	This Schedule D shall remain in full force and effect for the Term of the Agreement unless otherwise agreed between the Parties and, unless stipulated otherwise herein,
the terms of the Agreement shall apply hereto. 

 Therefore the Parties agree the following terms in relation to the maintenance
and repair of the Equipment:- 
 A. Patheon Responsibilities 

A.1. Patheon shall be responsible for the day to day maintenance and operating of the Equipment and the management of the preventative maintenance
thereof including managing the inventory and assuring availability of spare parts, change parts amd consumables. However, for the avoidance of doubt, Patheon shall not be liable for the cost of spares, additions, change parts or any other
componentry required for the continued running or servicing of the Equipment such costs to be borne solely by Zogenix. 
 A.2. Patheon
undertakes to use reasonable commercial efforts to maintain the Equipment in working order and such undertaking shall be considered discharged provided that Patheon has fulfilled the requirements of the preventative maintenance programme
(“PPM”) which shall be agreed and amended by the Parties from time to time. 
 A.3. The Equipment shall be insured by Patheon
for risks normally covered by Patheon’s third party property public liability insurance but shall be subject to the exclusions contained in Patheon’s “All Risks”) cover. 

 

 - - 52 - - 

 A.4. In the event any of the Equipment develops a fault or becomes unfit for purpose or incapable of
use, Patheon shall, provided such actions shall not be contrary to any rights of any third parties under the Deed or otherwise breach any warranties, endeavour to remedy the fault as quickly as is reasonably possible. Zogenix shall provide necessary
assistance to Patheon for the remediation thereof. In the event that additional work is required and, due to expediency, such work can be carried out successfully by Patheon and Patheon agrees to undertake such work then the cost thereof shall be
charged to Zogenix and paid in accordance with the terms of the Agreement. 
 A.5. Patheon shall not be liable or responsible for any
consequential damage including the loss of profits arising by reason of the Equipment being out of order from any cause. 
 A.6 Zogenix
authorizes Patheon to effect repairs on Equipment, either by Patheon employees or contractors, and Patheon shall only permit repairs by those employees or contractors who have been agreed by Zogenix as qualified to perform such repairs. Patheon
shall establish and maintain business relationships with contractors who are necessary to perform repairs which cannot be performed by Patheon employees. Patheon shall notify Zogenix in advance of performing major repairs; otherwise, within 48 hours
of effecting the repair. The cost of repairs shall be borne by Zogenix. In addition, Patheon shall maintain records of all Equipment maintenance, repairs, and spares replacement as required by cGMP and agreed between the Parties. Furthermore,
Zogenix authorizes Patheon to replace defective, damaged, worn-out, or non-functional components of Equipment as specified in a spare parts list and replacement instructions; such list to be agreed upon by the Steering Committee. Patheon shall
procure such parts directly from suppliers or through Zogenix, as the case may be, and maintain an inventory of such parts as specified on the spare parts list; the cost of spare parts shall be borne by Zogenix. 

B. Zogenix Responsibilities 

B.1. Zogenix shall insure the Equipment at all times. 

B.2. Zogenix shall pay for and provide all necessary spares. 

B.3. [***]. 
 B.4. In the event
Zogenix require external contractors to be present at Patheon’s site for the purposes of repairing or assessing the Equipment, Zogenix undertakes to ensure that all such contractors are approved by Patheon prior to being given access to the
Patheon site and adhere to all and any health and safety and environmental requirements whilst at Patheon. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 53 - - 

	B.5.	Zogenix shall be responsible and liable for any alterations and additions to the Equipment. 

C. Planned Preventative Maintenance List 

The Parties agree to develop and confirm a mutually agreeable planned preventative maintenance list and attach it hereto as soon as reasonably possible.

 D. General 

All terms and conditions of the Agreement are applicable to this Schedule D. In the event of any conflict between the terms herein and the Agreement then
the terms of the Agreement shall prevail. For the avoidance of doubt, however, nothing explicit or implied within the Agreement shall be construed as stating that ownership, risk and title to the Equipment remains and vests at all times with either
Zogenix or GE. 
 E. Equipment List 
  

									
	 Process Step
	 	 Description
	 	 Manufacturer / Vendor
	 	 Model Number
	 	 Serial No.

	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 54 - - 

									
	 Process Step
	 	 Description
	 	 Manufacturer / Vendor
	 	 Model Number
	 	 Serial No.

	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 55 - - 

									
	 Process Step
	 	 Description
	 	 Manufacturer / Vendor
	 	 Model Number
	 	 Serial No.

	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 56 - - 

 SCHEDULE E 

FORECAST MODEL 

Rental Fee Period: [***] 
  

	–	[***] 

	–	[***] 

	–	Expressed in Finished Packs 

	–	Forecast increments = Standard Batch Size converted into Finished Packs 

	–	For the pruposes of the models below it is assumed [***] 

					
	–	 		 	= Firm Order period

 As at [***] 

 

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 57 - - 

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 58 - - 

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 Tiered Pricing:
[***] 
  

	–	[***] 

	–	[***] 

	–	Expressed in Finished Packs 

	–	Forecast increments = Standard Batch Size converted into Finished Packs 

	–	[***] 

					
	–	 		 	= Firm Order period

  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 59 - - 

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 60 - - 

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	

 As at [***] 
  

																									
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 Rental Fee Period and Tiered
Pricing: [***] 
  

	–	[***] 

	–	Expressed in Finished Packs 

	–	Order increments = Standard Batch Size converted into Finished Packs ([***]) 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 61 - - 

 As at [***] 
  

																	
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

 - - 62 - - 

 As at [***] 
  

																	
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 As at [***] 

 

																	
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 As at [***] 

 

																	
	 	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Trade)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sumatriptan 6mg/0.5mL (Sample)
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Sodium Chloride 0.9% Solution
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 DoseProTM Unfilled Assembled Devices
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 - - 63 - - 

 SCHEDULE F 

SUPPLY CHAIN TELECONFERENCES AND INVENTORY REPORT 

Both Parties agree to monthly supply chain teleconferences or face-to-face meetings. The purpose of these meetings is for: 

 

	 	(i)	Patheon to provide updates on near-term Finished Good delivery schedule and potential delays; 

 

	 	(ii)	Patheon to provide updates on issues that may impact mid-term deliveries and/or component requirements; 

 

	 	(iii)	Zogenix to provide an informal intra-quarterly demand update if changes are foreseen to the previously issued forecast; 

 

	 	(iv)	Review of existing Firm Orders and what needs to be committed to before the next meeting; 

 

	 	(v)	Both parties to discuss long range component requirements and challenges; 

  

	 	(vi)	Review of outstanding invoices; 

  

	 	(vii)	Miscellaneous new business. 

 INVENTORY
REPORTS 
 For each Material supplied by Zogenix, as set out in Schedule C, Patheon shall provide to Zogenix, on a weekly basis, a report, in
a format mutually agreed by the Parties, that includes the following information: 
  

	(a)	Starting inventory at the beginning of the weekly period detailing the Patheon SAP code number, Patheon lot number and supplier lot number and expiry;

  

	(b)	A listing of Patheon SAP 101 and 102 transactions for that week detailing the Patheon SAP code number, Patheon lot number and supplier lot number;

  

	(c)	The quantity of materials consumed by batches of Product, media fill simulations and non-commercial activities for that week detailing the Patheon SAP code number,
Patheon lot number and supplier lot number; 

  

	(d)	The quantity of materials rejected for that week detailing the Patheon SAP code number, Patheon lot number and supplier lot number. 

 

 - - 64 - -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]